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This dissertation describes a microfluidic technique for the synthesis and preparation 
of tumor-targeted liposomes for drug delivery applications plus the utilization of 
these liposomes for innovative pharmaceutical and preclinical research applications. 
Microfluidic hydrodynamic flow focusing enables the production of nearly 
monodisperse populations of nanoscale liposomes while providing exquisite control 
over size in comparison to traditional bulk-fluid liposome synthesis methods. Here, 
the microfluidic process was first implemented using lipids functionalized with high 
molecular weight polymers and other molecules to determine the ability to prepare 
long-circulating, tumor-targeted liposomes. Additionally, the process was realized in 
thermoplastic microchannels which require simpler, less expensive fabrication 
methods than the silicon-based devices in which this technique was originally 
demonstrated. Second, additional functionalities were integrated into the microfluidic 
platform, including buffer exchange and remote drug loading in-line with liposome 
  
synthesis, to yield a continuous process for microfluidic preparation of liposomes 
containing high concentrations of amphipathic drugs which are commonly used for 
the treatment of cancer and other diseases. Next, the microfluidic technique, which is 
typically performed in two-dimensional rectangular microchannels, was implemented 
within a three-dimensional concentric capillary structure to assess the impact of edge 
effects during flow focusing on liposome synthesis in the two-dimensional system 
and to demonstrate a higher-throughput method for microfluidic liposome 
preparation. Along with exploring these additions to and variations upon the 
established microfluidic platform, microfluidic-enabled populations of liposomes 
were used for innovative pharmaceutical and preclinical research to demonstrate their 
utility in practical applications. First, nanoscale liposomes with discrete diameters 
were produced in order to investigate the effect of liposome size on cellular uptake 
mechanisms in vitro for a human epithelial colorectal adenocarcinoma (Caco-2) cell 
line. Next, liposomes with diameters below a proposed size cutoff for transdermal 
delivery (~40 nm) were produced to examine their ability to passively traverse layers 
of ex vivo porcine skin. The original research presented in this dissertation 
demonstrates the capacity to incorporate additional on-line liposome preparation 
functionalities into an established microfluidic technique, advances the platform to 
render it more amendable for widespread use, and highlights the advantages of 
microfluidic-prepared liposomes for practical applications through pharmaceutical 
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 : Introduction Chapter 1
1.1 Liposomes: Definition and Impact on Nanomedicine 
Liposomes are self-assembled vesicles composed of lipid molecules which sequester small 
aqueous volumes within an enclosed lipid bilayer. Existing in diameters ranging from tens of 
nanometers to hundreds of microns, liposomes have been used in a variety of applications 
ranging from biomedical research to cosmetic formulations,
1
 making a particularly high impact 
in the field of drug delivery.
2
 In addition to their capacity to encapsulate aqueous solutions 
within their core, liposomes are able to isolate lipophilic compounds within their lipid bilayer as 
well as support tailored surface chemistries for targeted delivery of these encapsulated 
compounds (Figure 1.1). Furthermore, liposomes are typically made from biodegradable, 
nontoxic, nonimmunogenic lipid molecules and resemble cellular membranes both in 
composition and structure, thus 
liposomal drug delivery systems have 
excellent biocompatibility, low toxicity, 




demonstrate improved efficacy and 
decreased toxicity over non-encapsulated 
conventional drugs,
4
 particularly for 
cancer applications due to their ability to 
accumulate within tumor 
microenvironments as a result of the 
Figure 1.1: Liposome with encapsulated drug 
molecules and functionalized membrane for 





enhanced permeation and retention (EPR) effect which enables nanoscale liposomes to passively 
target cancerous tissue through leakage from the characteristically porous neovasculature and 
insufficient drainage present in tumors.
5
 Liposomal anthracyclines (e.g., doxorubicin (DOX)) 
have exhibited similar efficacy with substantially reduced toxicity in comparison to traditional 
administration of non-encapsulated drugs for both adjuvant and metastatic breast cancer 
treatments.
6
 Liposome-encapsulated  reagents have also shown to be very effective for the 
treatment and diagnosis of a variety of cancers including ovarian cancer
7
 and other solid 
tumors,
8,9










1.2 PEG-and Folate- Modified Liposomes 
 Improved passive targeting for systemic administration of liposomes may be achieved 
through the use of “stealth” or long-circulating liposomes, which contain a flexible hydrophilic 
polymer such as poly(ethylene glycol) (PEG) on their exterior that occupies the space 
immediately adjacent to the liposome surface and excludes other molecules from binding to the 
vesicle.
3
 The protective shield provided through PEG prevents the attachment of serum proteins 
(opsonins) and subsequent recognition by the mononuclear phagocyte system, which would 
trigger an immune response and lead to rapid elimination of the liposomes during circulation in 
the bloodstream.
14
 The PEGylation of liposomes results in increased blood circulation time, 
allowing the drug carrier a longer timeframe to reach its target site before it is ultimately cleared 
from the bloodstream and has a toxic effect on healthy tissues such as the liver, kidney, and 
spline.
14
 As an example, studies have shown free drug, liposomal drug, and PEG-conjugated 
liposomal drug half-life times of 52 min, 260 min, and 665 min (respectively).
16
 
 In addition to attaching a protective barrier of PEG to liposomes to guard from unspecific 




may also be tethered to the terminal end of the PEG molecules to instigate specific uptake by 
targeted tissues. This active targeting strategy delivers liposomal drugs to their intended site by 
allowing the liposomes to efficiently and selectively dock with pathologic cells that overexpress 
high-affinity receptors for these ligands.
17,18
 While a range of macromolecules including 
antibodies, antibody fragments, lectins, and lipoproteins have been explored for targeted 
delivery,
19
 small molecule targeting ligands (MW < 500 Da) are particularly well suited for 
conjugation with nanoparticles due to their affordability, accessibility, and small molecular 
weight in comparison to the overall size of nanoparticles.
20
 Folate is a particularly attractive 
small molecule (441.4 Da) targeting ligand which is receiving increasing attention for selective 
drug delivery to cancer tissues.
21–24
 Possessing many advantages over competitor targeting 
moieties such as antibodies, folate is non-immunogenic, not prone to denaturation, highly stable, 
has simple and defined conjugation chemistry, has excellent specificity to tumors, and is readily 
accessible in large quantities.
25
 Folate is also compatible with organic solvents, which are 
necessary during the preparation of  liposomes and other types of nanoparticles.
25
 Folate 
receptors (FR) are greatly overexpressed in a wide range of cancer and inflammatory disease 
tissues, and folate binds to these receptors with an exceptionally high affinity.
21–25
 Finally, folate 
may be readily conjugated with liposomes using PEG linkers without affecting its activity.
18
 The 
low molecular weight, low cost, ease of conjugation, stability in diverse solvents and pHs, lack 
of immunogenicity, and high affinity for its receptor on target cells make folate a valuable choice 
as a targeting moiety for liposomal drug delivery systems.
21–25
 
1.3 Limitations of Contemporary Liposome Synthesis Techniques 
Despite the ongoing developments for targeted liposomal drugs, liposome synthesis remains 







 and alcohol injection.
30–33




methods rely on the self-assembly of lipid molecules into vesicles within environments which 
contain turbulent and uncontrolled fluid flows, resulting in large, polydisperse populations of 





) to control the size and reduce the polydispersity of the final 
sample. Liposome size and size distribution are critical factors for ensuring well-regulated drug 
dosage, proficient cellular uptake, and extended in vivo circulation time.
35,36
 Liposomes which 
are smaller in diameter have exhibited slower blood clearance rates, accordingly resulting in 
enhanced bioavailability and thus an improved opportunity to traverse tumor capillaries.
35,36
 In 
addition to improved circulation times, smaller liposomes show enhanced accumulation within 
tumor tissues and enhanced in vivo drug release.
37
 It has also been reported that both liposome 
uptake rate and final internalized concentration increase as particle diameter is reduced, further 
illustrating the impact of liposome size on delivery to cancer cells.
38
 Consequently, large, 
polydisperse liposome populations encompass lower safety profiles due to the need for higher 
concentrations of drug to be administered to achieve desired therapeutic indices.
38
 
As formerly mentioned, PEG- and ligand-conjugated liposomes have been developed to 
assist in alleviating the recognition of opsonins to increase blood circulation time and to enhance 
specific uptake by the tissues of interest. These decorated liposomes are typically generated 
through the appendage of these additional moieties to pre-formed vesicles, which entails 
additional processing steps for the post-insertion of functionalized lipids or conjugation of the 
ligands, further complicating the preparation of the liposomal drug
39
 and inevitably increasing 
the cost for development and manufacturing.
40
 The need to decrease liposome size in addition to 
developing a less laborious method for targeting ligand conjugation remain key challenges in the 
future advancement of liposomes as drug carriers. Therefore, liposomal drug delivery systems 




liposomal drugs with tunable sizes below the limits defined by contemporary bulk scale 
production methods, while supporting flexible protocols that may be optimized for specific 
liposome sizes, concentrations of encapsulated compounds, and functionalization of liposome 
membranes with targeting ligands.  
1.4 Continuous Flow Microfluidic Liposome Synthesis 
A microfluidic platform which supports one-step, continuous flow formation of nearly 
monodisperse liposomes of tunable sizes within a single device has previously been 
demonstrated.
41–44
 Microfluidics offers the exquisite manipulation of fluid flow conditions, 
allowing for the unique control over the self-assembly of lipids into liposomes. Specifically, this 
occurs through simultaneous control of interfacial interactions between fluid and chemical 
species, particle diffusion, and mixing of dissimilar fluid phases, a level of manipulation which is 
Figure 1.2: Schematic of the liposome formation process via hydrodynamic focusing in a 
microfluidic channel. Concentrations ratios of isopropanol (IPA) to aqueous buffer are 






not available in larger size scale batch preparation systems.
44
 Using a simple microfluidic flow 
focusing technique which incorporates the alcohol-injection synthesis method
30–33
 into a 
microfluidic chip, nearly monodisperse populations of liposomes with tunable sizes have been 
generated without the need for any post-processing steps to achieve unilamellarity or to reduce 
the size or size distribution.
41–44
 This method involves a center fluid stream of alcohol and 
solvated lipid which is sheathed by two oblique streams of aqueous buffer via microfluidic 
hydrodynamic focusing in a Y-channel microfluidic device (Figure 1.2). Due to the 
characteristically laminar flow (i.e. Reynolds number <2300; microfluidics generally has Re <1) 
plus the miscibility of alcohol in water, precise formation of nearly monodisperse populations of 
liposomes is achieved as a result of the controlled diffusive mixing at the nanoscale which occurs 
at the interface of the two fluid species, allowing the lipids to systematically diffuse into the 
aqueous buffer in which they are insoluble, forming unilamellar lipid vesicles of exceptionally 
Figure 1.3: Liposome size and size distribution at different flow rate ratios (FRRs). As 
the FRR increases by a factor of 6, resulting liposome size decreases in diameter from 
approximately 120 to 50 nm and the size distribution decreases from ±50 nm to ±10 nm 






consistent size.  By adjusting the ratio of buffer to alcohol volumetric flow rates and thus altering 
the flow focusing conditions, the size of the resulting liposome populations may be controlled 
(Figure 1.3).
41–44
 In comparison to bulk scale synthesis methods, this technique provides a one-
step, continuous flow process for the production of small, unilamellar liposomes without the 
need for additional homogenization steps.  
1.5 Microfluidic Filtration and Sample Purification 
The generation of liposomes
41–44
 as well as other types of nanoparticles
45,46
 in microfluidic 
devices has shown great promise due to the ability to produce on-demand, nearly monodisperse, 
highly controllable populations with less preparation steps compared to traditional bulk scale 
processes. However, microfluidic nanoparticle synthesis methods often result in samples 
containing unused solvents and compounds which are undesirable in the final solution, thus 
necessitating an additional off-chip purification step.  
Microfluidic separations are a widely exploited feature in microchannels in order to precisely 
control and direct small volumes of fluid.
47
 The sorting of nanoparticles formed by continuous 
flow microfluidics could be achieved through a variety of established separation methods. Free 
flow separations, which are characterized by continuous injection, real-time monitoring, and 
constant collection, are compatible with continuous flow microfluidic applications.
48
 Numerous 
continuous flow separation methods have been demonstrated in microfluidic devices, and 
although most have focused on micrometer-sized particles,
48
 a few techniques have proven 
feasible for the on-line separation of nanoparticles. First, microchannels could be fabricated in 
polyimide which would allow in situ integration of ion track-etched nanoporous structures for 
filtration.
49,50
 This method encompasses several advantages, such as high pressure operation and 
the ability to achieve 10 nm pore sizes; however, the microchannel aspect ratio would be limited 






 For microfluidic production of nanoscale liposomes, higher aspect ratios (6:1 or 
greater) are preferable
44
 and therefor e microchannels fabricated in polyimide would not be ideal. 
Another potentially viable method for microfluidic purification of nanoparticles is 
electrokinetic separation of the liposomes from the buffer. Electrokinetic-controlled microfluidic 
networks have proven useful for precise isolation of nanoscale biological samples.
52
 To facilitate 
this process, charged components could be incorporated into the bilayer lipid membrane in order 
to impose an overall charge on the liposomes. When anionic or cationic surfactants are 
incorporated into the liposomal bilayer at constant concentrations, the charged species are 
theoretically equally distributed throughout the membranes of all liposomes and thus the charge-
to-size ratio remains constant, enabling size-based electrokinetic separation due to the variance 
in net individual liposome charge.
53
 To be implemented, this method would need to be converted 
into a continuous flow separation technique, which has been demonstrated for free flow 
electrophoretic separation of amino acids in both aqueous and binary media.
54
 However, this 
version of electrokinetic separation necessitates an electric field above 1.5 kV/cm in order to 
accomplish the transverse purification, which could potentially cause lysis of fragile particles 
such as liposomes.
53
 In addition, the fundamental task for this application is to separate the 
liposomes from all other components of the buffer, thus any compounds with a charge (e.g., 
charged dyes, therapeutics, anionic membrane components, etc.) may also migrate under an 
electric field, consequently presenting numerous challenges for thorough purification. 
Accordingly, a rapid, transverse microfluidic filtration method which is appropriate for 
continuous flow separation of delicate, nanometer-scale particles must be implemented in order 
to achieve a highly purified sample of undamaged liposomes. A less common but well-fitting 
method of continuous flow filtration and rapid buffer, which circumvents issues associated with 




microfluidic device. Adequate 
porosities, flexibility, mechanical 
robustness, and compatibility with 
plastic microfluidic networks make 
commercially available polymeric 




addition, the large surface area-to-
volume ratio presented by porous 
membranes is particularly essential for 




Regenerated cellulose membranes 
comprise many advantages over other polymeric membranes for buffer exchange and 
nanoparticle sample filtration due to their high porosity, excellent chemical compatibility, and 
wide range of pore size availabilities in the sub-micrometer range.   
A microfluidic technique facilitating sample clean-up for electrospray ionization-mass 
spectrometry of nanoscale biological samples has been demonstrated using a commercially 
available regenerated cellulose membrane embedded in a thermoplastic device (Figure 1.4).
56,57
  
Efficient buffer exchange is achieved as a result of the chemical potential between the two 
compartments in combination with the transmembrane pressure gradient established by the 
dimensional variance between the sample channel and the buffer channel, plus the continuous 
buffer counterflow which causes the cleanest sample solution to be in constant contact with the 
cleanest dialysis buffer.
56
 This method utilizes both methods of dialysis, or displacement of 
Figure 1.4: Schematic of overlapping sample and 
buffer channels separated by a regenerated cellulose 
membrane (MWCO 8000) after alignment of the 
microchannel chips for microfluidic buffer exchange. 






solutes from a partition in which they are in high concentration to one in which they are diluted 
driven by the electrochemical gradient in the system, and ultrafiltration, or transport of a solute 
across a semipermeable membrane from one fluid compartment to another in response to a 
transmembrane pressure gradient.
56,57
 The result is a rapid, efficient method for microfluidic 
buffer exchange. This purification technique is compatible with microfluidic-directed liposome 
synthesis and would provide highly purified samples with minimal impact on the resulting 
populations of liposomes.  
1.6 Methods for Solute Encapsulation into Liposomes 
The unique ability to sequester small volumes of aqueous solutions within their core and 
confine lipophilic compounds within their bilayer is a key advantage of liposomal drug delivery 
systems. Various approaches for encapsulation of reagents into the liposomal core fall into two 
categories: passive and active loading. Passive encapsulation strategies rely on loading of 
compounds during liposome formation and are highly dependent on chemical properties. 
Although simpler, passive loading methods typically yield a loading efficiency of 5-20%
15
 while 
active loading techniques achieve 93-97% efficiency.
58
 Although methods such as lyophilization, 
evaporation, or freeze-thaw cycles may be employed to improve passive loading proficiencies,
15
 
passively encapsulated solutes can readily penetrate the membrane and thus are unstable, plus 
they necessitate post-formation filtration due to the large amount of remaining unloaded drug in 
the extra-liposomal buffer.
15
 Moreover, passive loading methods often result in polydisperse 
liposome sizes, difficulties with regularization, and low reproducibility.
15
   
Active encapsulation, or remote loading, methods involve systematic entrapment of 
therapeutics into pre-formed liposomes, typically utilizing a driving force such as a 
transmembrane pH- or ion-gradient.
59
 Remote loading techniques all comprise a similar concept: 




physiological pH conditions. 
Uncharged amphipathic weak 
bases (e.g., anthracyclines such 
as the commonly used DOX) are 
then incubated with the 
liposomes where they diffuse 
into the vesicles, becoming 
protonated intravesiculary and 
thus inhibiting membrane 
repermeation.
58
 This reaction 
ensues, resulting in an 
accumulation of anthracycline 
inside the liposome which leads 
to precipitation through drug 
self-association or precipitation with interior liposomal salts present in the buffer, achieving 
intravesicular drug levels that exceed the solubility of the drug.
60
 This method achieves 




Remote loading specifically through a transmembrane ammonium sulfate gradient is a 
widely-used, rapid, simple, stable, and efficient method of encapsulation for amphiphilic 
molecules such as anthracyclines into liposomes.
60
 For example, DOX is commercially available 
as Doxorubicin Hydrochloride (DOX-HCl), an amphipathic weak base which is both water and 
alcohol soluble. When introduced to liposomes with an acidic interior compared to their neutral 
environment, active entrapment occurs as a result of the base exchange with the ammonium ions 
Figure 1.5: Overview of the remote loading process. Here, 
an amphipathic weak base (doxorubicin, ‘DXR’) is actively 
driven into a pre-formed liposome through a 
transmembrane ammonium sulfate gradient. Adapted from 






inside the liposome (Figure 1.5).
60
 The first nanoparticle therapeutics approved for clinical use 
(Doxil
®
, a PEG-coated form of liposomal DOX), liposomal anthracyclines were developed to 
mitigate the cardiac and gastrointestinal toxicity triggered by conventional anthracyclines 
injected intravenously for the treatment of various epithelial cancers and other ailments while 
sustaining antitumor efficacy by altering tissue distribution and pharmacokinetics.
62
   
Moreover, the drug-to-lipid ratio is a very important detail to consider in liposomal drug 
delivery systems. Various lipid compositions and entrapment methods yield different entrapment 
efficiencies, fluctuating more with passive encapsulation than with remote loading techniques,
61
 
generating the probability of dosage uncertainty. There is evidence that the in vivo toxicity of 
liposomal DOX decreases with increasing drug-to-lipid ratios.
61
 Finally, a high drug-to-lipid 
ratio is likely to reduce the cost of formulations.
63
  
Smaller liposomes are advantageous to their larger counterparts due to their greater uptake 
rates and internalized liposome concentrations in cancer cells,
38
 ability to exhibit longer 
circulation times (and thus enhanced bioavailability
35,36
 and higher levels of accumulation within 
tumor tissues), and improved in vivo drug release.
37
 One caveat to this phenomenon is that 
smaller liposomes have a reduced interior volume and consequently less available space to retain 
encapsulated material. Hence, remote loading techniques prove even more vital for drug 
entrapment as the radius of the liposomes produced decreases in order to maximize the payload 
of drug delivered to the target site. Consequently, remote loading strategies provide enhanced 
stability, improved efficacy, reduced toxicity, and decreased manufacturing costs in comparison 
to passive loading strategies, and are extremely beneficial to reach high drug-to-lipid ratios and 




The established microfluidic network for liposome synthesis has previously been 
demonstrated to incorporate a method of passive encapsulation of hydrophilic molecules with the 
benefit of lower consumption of the solute to be encapsulated as a result of the narrowed fluid 
stream width of the solute-containing fluid kept close to the interface with the lipid/solvent 
stream where spontaneous liposome self-assembly occurs (Figure 1.6).
43
 Although advantageous 
for molecules which cannot be encapsulated through remote loading, one goal of this dissertation 
is to further evolve the established microfluidic technique to include on-line remote loading of 
amphipathic compounds in order to produce microfluidic-enabled populations of stable 
liposomal drugs at high concentrations.  
1.7 Medical Applications of Liposomes  
Liposomes are highly versatile nanoparticles which benefit applications across many fields of 
interest. Liposomes have provided important advancements for medicine, immunology, 
diagnostics, cosmetics, ecology, cleansing, and the food industry.
64
 Specifically for the medical 
field, liposomes have an immense clinical utility and have been developed as pharmaceutical 
carries for various practical applications,
65
 showing enhanced efficacies when delivered through 
Figure 1.6: (a) 5-inlet chip design, and (b) fluorescent micrograph of a hydrodynamically 
focused lipid/alcohol stream employing a passive encapsulation technique. Adapted from 
















 application. Liposomes 





 nucleic acids (e.g., DNA
77







Liposomes are also suitable to carry contrast reagents for various types of diagnostic imaging, 
including magnetic resonance imaging (MRI), computed tomography imaging (CTI), positron 
emission tomography (PET), and sonography.
81
 Furthermore, enhanced manipulation of 







 and ultra-flexible transferosomes.
74
 
The multitude of advancements for liposomes as pharmaceutical and diagnostic reagent carriers 
continues to increase; therefore, an enhanced preparation method which provides purified 
liposomal drugs or imaging reagents at high concentrations through a one-step, continuous flow 
process would greatly improve the effectiveness of liposomes for practical applications and 
greatly benefit the medical field.  
1.8 Motivation and Global Hypotheses 
 Microfluidic-directed liposome synthesis provides an alternative approach for vesicle 
production with various benefits over bulk-scale production methods, including lower levels of 
polydispersity, high control over resulting vesicle size, . The motivation behind this research is to 
evolve the existing microfluidic technique to make it more amendable for widespread use and to 
highlight the benefits of the technique through actual preclinical applications. The addition of 
downstream functionalities to the microfluidic liposome synthesis method such as active drug 
encapsulation would enable point-of-care liposomal drug production by generating customized 
formulations in a one-step process. The advantages of microfluidic systems will be exploited to 
form new processes for the synthesis of liposomal drugs. For example, it is hypothesized that the 




radially symmetrical flow focusing will further decrease the polydispersity of the resulting 
liposomes. In addition, the high level of size control together with the significantly low levels of 
polydispersity enabled by the microfluidic liposome synthesis method could assist in the 
exploration of new pharmaceutical and preclinical research applications, including size-
dependency of cellular uptake mechanisms and passive transdermal uptake of liposomal carriers. 
This dissertation explores the pilot microfluidic method for liposome synthesis through the 
implementation of these concepts. 
1.9 Dissertation Overview 
The ability of a microfluidic technique to form liposomes encompassing a range of fine-
tuned diameters, tailored surface chemistries, and encapsulated therapeutics is demonstrated 
within the subsequent chapters. In addition, the usefulness of these liposomes with optimized 
properties provided through the meticulous control over their characteristics enabled by 
microfluidic preparation is highlighted through their use in innovative research applications. This 
dissertation focuses on pharmaceutical research investigating drug carrier optimization using in 
vitro studies and preclinical research to examine transdermal delivery of liposomes though ex 
vivo application of liposomes to porcine skin. These are just two practical uses among a vast 
collection of purposes in which the microfluidic method for liposome synthesis has potential to 
further advance the already burgeoning topic of liposomes in the medical field.    
The goal of the research presented through this dissertation is to evolve the established 
microfluidic hydrodynamic focusing technique for liposome synthesis from its preliminary state 
to a more amendable platform for widespread use and to demonstrate the benefits of liposomes 
synthesized through the technique through actual preclinical research applications. The 
dissertation is organized around the following interrelated topics, with the presentation of each 




Chapter 1: Demonstrate the microfluidic technique for liposome synthesis using 
functionalized lipids (specifically, PEG and PEG-folate) for continuous flow 
production of long-circulating, tumor-targeted liposomes. In addition, establish the 
method within thermoplastic microfluidic devices which utilize simple, scalable, low-
cost fabrication techniques. Adapted from Hood, et al., 2013.
86
 
Chapter 2: Incorporate on-line sample cleanup and remote drug loading to the liposome 
synthesis technique to enable production of liposome populations requiring no 
additional dialysis or separation methods together with rapid liposomal encapsulation 
of cancer-targeting compounds, opening the door to “pharmacy-on-a-chip” drug 
formulations suitable for on-demand applications. Adapted from Hood, et al., 2014.
87
 
Chapter 3: Perform the microfluidic liposome synthesis technique within a concentric 
capillary device to both investigate the effect of radially symmetric, three-
dimensional flow focusing on liposome production as well as address the issue of 
scale up by producing liposomes at greater volumetric flow rates. Adapted from 
Hood, et al., 2014.
88
 
Chapter 4: Investigate the effect of liposome size on cellular uptake mechanisms with high 
resolution by examining the interaction of microfluidic-prepared liposomes with 
human epithelial colorectal adenocarcinoma cells (Caco-2) in vitro, taking advantage 
of the technique’s unique ability to produce populations of distinctly-sized, nearly 
monodisperse functionalized liposomes. Adapted from Andar, et al., 2014.
89
 
Chapter 5: Demonstrate passive transdermal uptake of liposomes through ex vivo sections of 
porcine skin by utilizing the microfluidic liposome synthesis technique to generate 
liposomes below the proposed size cutoff for transdermal delivery of nanoparticles. 






 : Microfluidic Synthesis of PEG- and Folate-Conjugated Chapter 2
Liposomes for One-Step Formation of Targeted Stealth Nanocarriers  
2.1 Summary 
A microfluidic hydrodynamic flow focusing technique enabling the formation of small and 
nearly monodisperse liposomes is investigated for continuous flow synthesis of poly(ethylene 
glycol) (PEG)-modified and PEG-folate-functionalized liposomes for targeted drug delivery. 
Controlled laminar flow in thermoplastic microfluidic devices facilitated liposome self-assembly 
from initial lipid compositions including lipid/cholesterol mixtures containing PEG-lipid and 
folate-PEG-lipid conjugates. The relationships between flow conditions, lipid composition, and 
liposome size were evaluated, and the impacts of these parameters on PEG and folate 
incorporation were determined through a combination of UV-vis absorbance measurements and 
characterization of liposome zeta potential. Both PEG and folate were successfully incorporated 
into microfluidic-synthesized liposomes over the full range of liposome sizes studied. The 
efficiency of PEG-lipid incorporation was found to be inversely correlated with liposome 
diameter. Folate-lipid was also effectively integrated into liposomes at various flow conditions. 
Liposomes incorporating relatively large PEG-modified and folate-PEG-modified lipids were 
successfully synthesized using the microfluidic flow focusing platform, providing a simple, low 
cost, rapid method for preparing functionalized liposomes. Relationships between preparation 
conditions and PEG or folate-PEG functionalization have been elucidated, providing insight into 
the process and defining paths for optimization of the microfluidic method toward the formation 






Liposomes possess a range of highly attractive characteristics which make them excellent 
drug delivery vehicles. However, despite ongoing advances in the development of targeted 
liposomal drugs, their preparation remains a cumbersome bulk scale process based on classical 
bulk synthesis methods which require laborious post-processing steps to control the size and 
reduce the polydispersity of the resulting liposome population.
91
 Using a simple microfluidic 
flow focusing technique which integrates the alcohol-injection method into a microfluidic 
device, nearly monodisperse populations of unilamellar liposomes with controllable sizes have 
been realized without the need for any post-processing steps to reduce size variance (Figure 
2.1).
41–44
 The excellent control over fluid flow conditions provided by microfluidics offers a 
Figure 2.1: (a) Photograph of the thermoplastic liposome synthesis chip, and (b) 
numerical simulation of hydrodynamic flow focusing in the microfluidic device, 
illustrating the diminishing mole fraction of ethanol along the center of channel as the 
alcohol (red) and aqueous buffer (blue) streams interact at a flow rate ratio of 70 within a 




unique path to liposome self-assembly through manipulation of interfacial interactions, particle 
diffusion, and convective-diffusive mixing of fluid phases.
44
 However, the attachment of ligands 
such as PEG or targeting moieties to pre-formed liposomes can require additional processing 
steps for the post-insertion of functionalized lipids, further complicating established methods of 
liposomal drug preparation
39
 and inevitably increasing the cost for development and 
manufacturing.
40 
Previous work on liposome production using the microfluidic flow focusing technique has 
concentrated on exploring the impact of changes in the ratio of volumetric flow rates between the 
buffer and alcohol streams on mean liposome size using a single native lipid species.
41,42,44
 This 
chapter explores microfluidic flow focusing as an effective method for the continuous flow 
preparation of nanoscale liposomes functionalized with PEG, enabling rapid and automated 
formation of stealth liposomes, and further extending the technique to the formation of liposomes 
functionalized with folate-PEG conjugates. The resulting functionalized liposomes containing a 
combination of native lipids, PEG-lipids, and folate-PEG-lipids are characterized using a variety 
of analytical methods to explore the impact of microfluidic flow parameters on liposome size and 
surface properties. Asymmetric flow field-flow fractionation (AF
4
) paired with multi-angle laser 
light scattering (MALLS) and quasi-electric light scattering (QELS) is used to evaluate size 
distributions of liposome populations formed under varying flow conditions and lipid 
compositions. To investigate the incorporation of the various lipid conjugates into the liposomes, 
UV-visible absorption spectroscopy, zeta potential measurements via phase analysis light 
scattering, and cryogenic temperature transmission electron microscopy are employed. Based on 
measurement results, the microfluidic platform is shown to provide a rapid, one-step method for 
preparing nearly monodisperse populations of folate receptor-targeted stealth liposomes of 




In addition to evaluating the microfluidic technology as a suitable method for on-line 
formation of functionalized liposomes, this chapter presents several ancillary advancements over 
previous studies. Unlike established efforts based on the use of silicon and glass microfluidic 
platforms, the application of thermoplastic microfluidics has been explored as an alternative 
technology platform suitable for low-cost scale-up of the liposome synthesis technique. 
Furthermore, while prior studies have employed relatively toxic solvents such as isopropyl 
alcohol as a lipid carrier during microfluidic flow focusing,
41,42,44
 this work utilizes ethanol as a 
less toxic solvent system to enhance biocompatibility for future in vivo applications.  
2.3 Materials and Methods 
2.3.1 Device Fabrication 
Microfluidic devices were fabricated in cyclic olefin copolymer (COC), a low-cost 
thermoplastic with excellent compatibility with a wide range of organic solvents, using a 2-step 
hot embossing process in which microfluidic channel features were first milled onto a polished 
Alloy 260 brass sheet (McMaster-Carr, Dayton, NJ) using a precision computer numerical 
control (CNC) milling machine (MDX-650A; Roland, Lake Forest, CA). The brass template was 
cleaned with a mild detergent, placed in a sonicator for 15 min, and examined under a 
microscope for imperfections. The brass template was then stacked in a commercial hot press 
(Carver, Wabash, IN) with a 48 mm thick polycarbonate plate (McMaster-Carr, Dayton, NJ) and 
held at a pressure of 0.8 MPa and temperature of 170 °C for 5 min. The polycarbonate template 
with inverted channel features was then placed in the hot press with a 2 mm thick sheet of COC 
(Zeonor 1060 R, Zeon Chemicals L.P., Louisville, KY) and held at 0.4 MPa and 128 °C for 10 




Using a LV-100 UDM microscope (Nikon, Melville, NY) for optical profilometry, microchannel 
dimensions were found to be approximately 270 μm deep by 190 μm wide.  
A cover plate with fluidic access ports was fabricated from a second 2 mm COC sheet using 
a CNC milling machine, and both COC pieces were degassed at 70 °C under vacuum overnight. 
The chips were mated using solvent bonding with vapor-phase cyclohexane by placing the cover 
plate face down on top of a sealed glass beaker containing anhydrous cyclohexane (Sigma-
Aldrich, St. Louis, MO) at 30 °C, with the chip surface 5 cm away from exposed solvent, for 8.5 
min. The chips were aligned and bonded in a hydraulic press (Carver, Wabash, IN) at 1.9 MPa 
for 1 min at room temperature. The bonded COC was held at room temperature for at least 24 h 
before use to maximize bonding strength. Press-fit needles were inserted at each fluidic access 
port and attached to nanoport fluidic connectors (Upchurch Scientific, Oak Harbor, WA) and 
silica capillary tubing (Polymicro Technologies Inc., Phoenix, AZ). The device was attached to 
glass gastight syringes (Hamilton Co., Reno, NV) containing buffer and lipid solution. Two 
programmable syringe pumps (Harvard Apparatus, Holliston, MA) were used for fluidic delivery 
and control.  
2.3.2 Lipid Mixture and Hydration Buffer Preparation 
For PEG-modified (PEGylated) liposomes (PL), 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC), cholesterol, and 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-
N-[methoxy(polyethylene glycol)-5000] (PEG5000-PE) (all from Avanti Polar Lipids Inc., 
Alabaster, AL), and dihexadecyl phosphate (DCP) (Sigma-Aldrich, St. Louis, MO) were mixed 
in chloroform (Mallinckrodt Baker Inc., Phillipsburg, NJ) in the following proportions: 
DMPC/cholesterol/DCP/PEG5000-PE in molar ratio (50-x):40:10:x, where x = 0, 5, 10, creating 
liposomes with 0 mol %, 5 mol %, and 10 mol % of PEG5000-lipids. For folate-targeted 




phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG2000-PE), and 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[folate(polyethylene glycol)-2000] (PEG2000-Folate-PE) 
(all from Avanti Polar Lipids Inc.), and DCP (Sigma-Aldrich) were mixed in chloroform 
(Mallinckrodt Baker) in the following proportions: DMPC/cholesterol/DCP/PEG2000-
PE/PEG2000-Fol-PEin molar ratio 40-x:40:10:10:x, where x = 0 or 2, as well as 
DMPC/cholesterol/DCP (50:40:10), creating PEGylated and folate-receptor targeted liposomes 
with 2 mol % PEG2000-Fol-PEand both PEGylated and non-PEGylated liposomes as controls.  
The anionic surfactant DCP was included in all lipid preparations to prevent aggregation of 
liposomes in populations which did not contain PEG, as well as to assist in zeta potential 
measurements performed on all PLs.  For PLs and FPLs, the lipid mixtures were prepared in 
scintillation vials then placed in a vacuum desiccator for at least 24 h to allow complete solvent 
removal. The dried lipid mixtures were then redissolved in anhydrous ethanol (99.5% Sigma-
Aldrich) for a total lipid concentration of 20 mM. A 20 mM solution of 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) at pH 7.5 (Sigma-Aldrich) was used as an aqueous 
buffer in the microfluidic device. All solutions (solvent and buffer) were passed through 0.22 μm 
filters (Millipore Corp., New Bedford, MA) before being introduced to the microfluidic device. 
2.3.3 Microfluidic Liposome Synthesis 
Liposomes were prepared by injecting the lipid-solvent mixture between two buffer inputs 
into a microfluidic device, as done previously.
42
 HEPES buffer was injected into two oblique 
side channels intersecting with the center channel. The flow rate ratio (FRR), which is defined as 
the ratio of the volumetric flow rate of aqueous buffer to solvent, was set to 40, 70, and 100 for 
each PEG-lipid concentration to prepare PLs. The linear flow velocity of the combined fluid 
stream within the liposome formation channel was kept constant for all FRR values at 0.125 m/s, 




was observed with a TE-2000 S epifluorescence inverted microscope (Nikon, Melville, NY) 
throughout the liposome formation process to monitor for consistent flow conditions. 
2.3.4 Asymmetric Flow Field-Flow Fractionation (AF
4
) with Multi-Angle Laser Light 
Scattering (MALLS) and Quasi-Elastic Light Scattering (QELS) and UV-Vis Absorption 
Spectroscopy 
High-resolution size-based separations of the liposome populations were carried out with 
AF
4
. This fractionation method is useful for characterizing nanoparticles through high resolution 
separation. Because the nanoparticles are sorted by size and eluted at different time intervals 
based on size, the subsequent light scattering measurements provide highly detailed descriptions 
of each sample size which exists in the sample and reveals the presence of any aggregates or 
micelles in the liposomal solution. The AF
4
 system is well-maintained at the National Institute of 
Standards and Technology and is calibrated at least every few months using bovine serum 
albumin (BSA) and the system’s ability to separate the trimers, dimers, and monomers within the 
BSA solution. 
HEPES buffer was used as a carrier buffer for the AF
4
 separations. This was combined with 
MALLS, QELS, and UV-Vis absorption for liposome detection and characterization (DAWN 
EOS and QELS, Wyatt Technology, Santa Barbara, CA). A vendor-supplied spacer (250 μm 
thickness) was used to define the flow channel thickness with a 10 kDa molecular weight cut-off 
regenerated cellulose membrane for the cross-flow partition (Millipore, Bedford, MA). The flow 
was controlled with Eclipse 2 software (Wyatt Technology, Santa Barbara, CA). A sample 
volume of 30 μL (all samples) was injected at a flow rate of 0.1 μL/min while focusing at 1.5 
mL/min for 5 min. The injection step was succeeded by a second focusing step of 1.5 mL/min 
for 5 min. The crossflow was ramped linearly from 0.5 mL/min to 0 mL/min over a 30 min 




measured using the MALLS and QELS detectors with data processing using ASTRA software 
(Wyatt Technology). Static light scattering intensity (λ=690 nm) was measured at 15 angles 
simultaneously. The sample was analyzed at 1 s intervals by MALLS and 5 s intervals by QELS. 
The autocorrelation function of the QELS was fitted to a single-mode exponential decay model 
to resolve the hydrodynamic radii of the liposomes. A coated sphere model (i.e. a spherical 
structure with two radial regions of differing refractive index) of the MALLS data was consistent 
with this particle architecture and was used for size analysis of the geometric radius of the 
fractionated liposome samples. The ASTRA software generates information on the differential 
size distribution of each sample, which was used to analyze each population of liposomes. The 
differential distribution of each fractionated liposome sample produced a unimodal, sharp 
Gaussian distribution, indicating nearly monodisperse population with a continuous size 
distribution. The modal diameter was taken to be the average diameter of each liposome 
population, in addition to the full width at half maximum (FWHM) to account for any 
polydispersity in the sample. In addition, UV-vis absorption spectroscopy was also used in-line 
to detect the presence of PEG on PLs (λ=520 nm) and folate on FPLs (λ=280 nm) in the 
fractionated samples.  
2.3.5 Zeta Potential from Phase Analysis Light Scattering 
The PL zeta potential was determined using phase analysis laser light scattering (ZetaPALS, 
Brookhaven Instruments Corp, Holtsville, NY) using undiluted PL samples (1.5 mL). All 
liposome mixtures used for zeta potential characterization contained 10 mol % DCP as an 
anionic surfactant, and were prepared in a low conductivity buffer (20 mM HEPES, conductivity 
~60 μS). The incorporation of anionic DCP aided in electrophoretic measurements by providing 
the liposomes with a consistent surface charge density for each liposome sample. Electrophoretic 






Zeta potential measurements extrapolated from electrophoretic mobility measurements were 
averaged over 5 replicate runs of 10 cycles each. All measurements were carried out at 23 °C. 
2.3.6 Cryo-TEM Analysis 
Aliquots from PL samples containing 0% and 10% PEG-lipid (FRR 40) were imaged using 
cryo-TEM. Sample preparation for cryo-TEM investigation was carried out using a Cryoplunge 
3 unit (Gatan, Inc., Pleasanton, CA). A 3 μL volume of sample from 0%-PEG and 10%-PEG 
liposomes was pipetted onto a support grid held by tweezers directly above the cryoplunge 
workstation. The grid was aligned with the blot pads and was subsequently blotted for 4 s, giving 
a thin film between 100 nm-200 nm. The grid was then plummeted into liquid ethane in the 
workstation held at a temperature below -170 °C with liquid nitrogen. This was repeated for both 
liposome samples and the grid was transferred to a cryo-holder for examination via transmission 





Figure 2.2: Size distributions for liposomes composed of 0%, 5%, and 10% PEG-PE at 
each FRR. With increased flow focusing (higher FRR values), the diameters of the 
liposomes decrease in size. This trend is seen across all populations of liposomes, as well 






2.4.1 Impact of PEG on Liposome Size and Distribution 
MALLS and QELS in-line with AF
4
 provided size information about the populations of 
liposomes produced by the microfluidic device. A single peak was present in each set of light 
scattering data obtained for all PL samples, indicating the presence of one primary species in the 
liposome samples with no aggregate formation (data not shown). The average geometric radii of 
the particles were determined by comparison against a coated sphere model (provided in the 
ASTRA software) and converted to diameters (Figure 2.2). The modal diameter was taken as the 
average for each population (Figure 2.3).The size distributions of the liposomes followed the 


























Figure 2.3: Average geometric diameters of liposomes synthesized from lipid solutions 
with 0%, 5%, and 10% PEG-PE. Error bars are derived from the differential distribution 
of each liposome population, taken as the full width at half maximum divided by the 




overall trends observed in former studies, which demonstrated that liposome size is influenced 
by the flow focusing conditions with size declining as the magnitude of flow focusing increases 
(i.e. higher FRRs).
41,42,44
 The increased mismatch of fluid velocities between the alcohol and 
aqueous buffer flow streams as well as the narrower width of the alcohol flow stream, and 
therefore decreased diffusion lengths, observed at higher FRRs are thought to play a role in 
decreasing the size of the liposomes produced.
93
 Unlike these previous studies of liposome 
synthesis by microfluidic hydrodynamic focusing, which employed hybrid silicon/glass chips, 
the present work was performed using low-cost thermoplastic chips. It is notable that although 
the microchannel geometries, aspect ratios, roughness, precision, and surface properties all 
varied significantly from the previous silicon/glass chips, the devices were successful in 
producing size-tunable liposome populations with similarly low polydispersity as previous work, 
albeit with somewhat different relationships between flow rate ratio and mean liposome 
diameter. 
2.4.2 Characterization of PEG Incorporation into PLs 
The integration of PEG-lipids into PLs was first characterized through zeta potential 
measurements (Figure 2.4). Zeta potential measurements are useful for determining the level of 
surface coverage by a flexible polymer (i.e. PEG), with a decrease in the absolute value of zeta 
potential corresponding to an increase in PEG grafting on the liposome surface.
94
 This decrease 
corresponds to one of two phenomena: 1) the slipping plane, or the plane where the fluid directly 
adjacent to the particle becomes mobile,
95
 being moved farther away from the liposome’s outer 
surface and thus decreasing the absolute zeta potential, or 2) the physical drag caused by the 
incidence of long PEG chains on the liposome’s exterior membrane leaflet, hence reducing the 






All PL samples exhibited a negative zeta potential due to DCP present in the liposomes, 
which decreased in absolute value as the PEG-lipid content of the liposomes increased. The 
absolute value of zeta potential remained relatively constant across the range of sizes produced, 
with the exception of the largest size formed at the lowest FRR for 10% PEG-PE. 
Zeta potential represents the electrokinetic potential of the liposome at a distance from the 
outer membrane surface and expresses the degree of repulsion of adjacent particles from one 
another; it is a function of both particle surface charge and the nature of the surrounding 
environment including surface-bound ligands and thus is a useful tool for investigating the 
surface characteristics of PEGylated liposomes.  






























Figure 2.4: Zeta potentials of 0%, 5%, and 10% PEG-PE liposomes. The absolute value 
of zeta potential decreased with increasing PEG-PE content at each given size, indicating 
the shielding effect of DCP, an anionic surfactant included in the liposomes, by the PEG 




All liposome populations in this study contain equivalent concentrations of anionic DCP 
(10 mol %) and therefore have approximately equal negative net surface charge per unit area of 
membrane. However, the long, hydrophilic chains of PEG5000 serve as a shield to the liposome 
exterior, obstructing the negative surface charge provided by anionic DCP. Thus an increase of 
PEG molecules within the double layer will reduce the absolute value of the zeta potential due to 
the shielding effect of PEG on the negatively-charged liposome surface. Although a small 
amount of ethanol is present within each sample, the low mole fraction of ethanol in water at the 
various FRRs used does not result in significant changes in viscosity or dielectric constant,
97
 and 
thus does not appreciably alter liposome mobility.  
Zeta potential measurements performed using microfluidic-synthesized liposomes convey 
successful integration of PEG-modified lipids into the liposomes. As revealed in Figure 2.4, zeta 
potential is inversely correlated with PEG-PE concentration over the full range of liposome sizes 
studied here, confirming an increase in shielding of lipid charge resulting from higher surface 
density of PEG in the liposomes at higher PEG-PE concentrations. Overall, the decrease in the 
magnitude of zeta potential with increase in PEG-PE content provides strong confirmation that 
the PEG-lipid conjugates are successfully incorporated into the bilayer during the microfluidic 
flow focusing process.  
Incorporation of PEG lipids into PLs was further evaluated using absorption spectroscopy 
measurements performed in-line with AF
4
. Figure 2.5 depicts absorbance measurements over 
the same ranges of FRR and PEG5000-PE concentration employed in the previous set of 
experiments. The presented data reflects the integrated absorbance at λ=520 nm measured over a 
3 min AF
4
 elution time centered at the liposome elution peak to account for variations in 
liposome size distributions at each FRR. Note that the AF
4
 fractionation ensures that any free 




measurements in this test, which solely reflect the absorbance of the liposomes themselves. The 
integrated absorbance values presented in Figure 2.5 are further normalized to the maximum 
level measured in this set of experiments.  
Finally, PLs were analyzed with cryo-TEM imaging with 0 and 10 mol% PEG5000-PE to 
verify liposome size and lamellarity. The cryo-TEM images of the 10% PEG liposomes did not 
reveal any form of micelles or aggregates, which supports the previous arguments that all PEG-
lipids were incorporated into the liposomal membranes (Figure 2.6).  












































Figure 2.5: Absorption measurements at λ=520 nm performed in line with AF
4
 for 0%, 
5%, and 10% PEG-PE liposomes. Each datum reflects the integrated absorbance intensity 
over a 3 min elution period centered on the liposome elution peak. Liposomes with 5% 





2.4.3 Characterization of Folate Incorporation into FPLs 
To evaluate the incorporation of folate-PEG lipids into FPLs, quantitative analysis of the 
concentration of folate in the liposomes was enabled by absorbance measurements taken at 
λ=280 nm after being fractionated via AF
4







 the concentration of folate was determined by UV-Vis absorption measurements 
performed in-line with AF
4
. A comparison of the measured folate content as a percentage of the 
hypothetical folate concentration calculated from the lipid mixture introduced for the given flow 
conditions is presented in Figure 2.7. Absorbance values obtained for control liposomes were 
used as a baseline for all measurements to account for the absorbance caused by native lipid 
species. All of the resulting liposome populations, formed using a lipid mixture containing 2 mol 
Figure 2.6: Cryo-TEM images of liposomes formed using a lipid solution containing (a) 
0% and (b) 10% PEG-lipid. Imaging results confirm the formation of unilamellar vesicles 
absent micelles or aggregates in both cases. Small ice crystals or artifacts that commonly 
form during vitrification, sample transfer, or elevation of specimen temperature due to the 
electron beam during cryo-TEM imaging seen in several images
105
 do not reflect the 




% PEG2000-Folate-PE, showed a single peak of maximum absorbance coincident with the peak 
signal from light scattering, confirming that folate is only present in the liposome sample and is 
not eluted at a later time point as an aggregate. Folate content for FPLs was in general agreement 
with the calculated values. Additionally, a small signal was seen for PLs, indicating the presence 
of an additional species (PEG) on these vesicles (data not shown).  





























10% PEG-PE + 2% Folate-PEG-PE
Figure 2.7: UV-vis absorption data in line with AF
4
 from folate (10% PEG-PE + 2% 
folate-PEG-PE) liposome samples, normalized to control (0% PEG-PE + 0% folate-PEG-
PE) liposomes. Experimental values of liposome folate content are overall in agreement 





Ongoing developments in the field of nanotechnology are enabling advances in drug delivery 
systems based on precisely engineered and functionalized nanoparticles. In particular, liposomes 
are a widely exploited class of nanoparticles due to their advantageous qualities and have played 
a noteworthy role in recent pharmacological advancements.
65
 Despite rapid growth in 
nanoparticle-enabled therapeutics, there remain significant limitations which must be addressed 
in order for nanoparticles to reach their full potential as pharmacological agents. Key challenges 
facing existing nanoparticle systems include restricted particle size control and reproducibility, 
high cost of production, challenging and costly methods for realizing  tailored formulations, and 
indeterminate stability of the resulting therapeutic nanoparticles.
99,100
  
Nanoparticle behavior in vivo can vary drastically as a function of size, with significantly 
dissimilar pharmacokinetics and biodistribution resulting from small size variations.
101
 The 
synthesis of liposomes possessing well-defined sizes is particularly challenging, with 
conventional preparation methods commonly relying on poorly-controlled self-assembly of 
amphipathic constituents in turbulent flows, resulting in broad size distributions that require 
multiple post-processing steps to reduce polydispersity. This constraint increases both the time 
and cost of production, using processes that are further limited by the precision of the available 
materials used for the post-processing modification steps (e.g., size irregularity of nanometer-
scale pores in polycarbonate membranes used for extrusion). The microfluidic method employed 
here enables controlled formation of liposomes by utilizing the intrinsic property of lipids to 
systematically self-assemble under laminar flow profiles which facilitate controlled diffusive 
mixing between miscible fluids and lipid species that exhibit differential solubility within the 
diffusing fluid streams. Microfluidic-directed formation of liposomes is a rapid process that 




significantly smaller than liposome populations obtained through conventional bulk scale 
methods. At the same time, it is a single-step in-line process that eliminates the need for 
additional steps and equipment to be used for size homogenization. A central advance in the 
present work lies in application and characterization of the microfluidic technique toward the 
formation of functionalized liposomes, including the appendage of PEG and folate as a targeting 
ligand to the liposomal exterior, in a simple one-step process. Moreover, because the 
microfluidic technique eliminates the need for time consuming post-processing size 
homogenization and ligand insertion, liposomes may be rapidly prepared with custom 
formulations. This concept offers future potential for point-of-care applications, reducing the 
need for liposome preparations to maintain a prolonged shelf life. For example, liposomes with 
encapsulated enzymes and proteins have a limited shelf life, in some cases on the order of only 
hours or days, when simple electrostatic stabilization is employed.
1
 As a more aggressive future 
application of the technology, the microfluidic technique may also offer a path to on-demand 
synthesis of personalized drug formulations based on custom dosing, drug mixtures, or targeting 
ligands. The microfluidic technique is also shown to produce functionalized liposomes with 
tunable size and extremely narrow size distribution. It is expected that this feature will improve 
control over dosage while allowing more accurate prediction of the therapeutics’ fate in vivo. In 
addition, the ability to synthesize narrow distributions of functionalized liposomes will enable 
unique pharmaceutical research opportunities, such as the investigation of pharmacokinetic and 
pharmacodynamic relationships across a range of liposome sizes which are nearly impossible to 
accurately assess using traditional methods.  
 Here the ability to produce liposomes of tunable size with narrow size distributions is 
demonstrated, similar to previous studies,
41,42,44
 but within a low-cost thermoplastic microfluidic 




glass wafers and nanoports) as well as expensive, unnecessarily complicated fabrication 
techniques involving photolithographic patterning and high aspect ratio etching methods such as 
deep reactive ion etching. The present study abolishes the need for expensive materials and 
processes by exhibiting the ability to produce nearly monodisperse liposomes in a continuous 
flow process similar to previous studies within microchannels created in thermoplastic 
microfluidic chips via a two-step hot embossing technique, utilizing simple, inexpensive 
fabrication methods with much lower processing times. The transition from silicon to 
thermoplastic devices enables the microfluidic-directed liposome formation technique to be 
easily adopted in settings without cleanroom capabilities and significantly reduces the cost of 
device production. In addition, the use of inexpensive replication methods for microfluidic chip 
fabrication presents a realistic and cost-effective path toward parallelizing the synthesis process, 
using multiple flow focusing chips acting in tandem for the rapid production of large volumes of 
liposomes. 
Unlike previous work using isopropanol as a solvent for microfluidic-assisted liposome 
formation, here ethanol has been employed as a lipid carrier. The use of ethanol is significant for 
in vivo applications as its toxicity is significantly lower than that of other organic solvents, with a 
lethal blood level between 350–500 mg/dL, compared with 130–200 mg/dL for both methanol 
and isopropanol.
102
 While solvents other than ethanol may also be suitable for use with the 
microfluidic technique, each must be evaluated on an individual basis. For example, because 
chloroform is immiscible in water, the microfluidic method is not compatible with chloroform as 
a lipid carrier. Other carriers that are both miscible in water and compatible with the COC 
substrates used in these studies, such as butanol, are likely to be feasible. However, the lateral 
distribution of solvent during flow focusing, and thus the point at which lipids self-assemble into 




viscosity and solvent concentration across the diffusive water/solvent interface,
44
 and thus the 
size distributions of the resulting liposomes are expected to vary with solvent selection. 
While prior work has focused on relationships between flow conditions and liposome size 
using native lipids, here the focus is to evaluate the impact on liposome size and size distribution 
by the addition of PEG5000-lipid to the initial lipid mixture used in the microfluidic flow 
focusing process. The microfluidic device produced narrowly-distributed populations of 
liposomes with an overall decrease in liposome size with an increase in FRR, regardless of the 
presence of PEG-PE in the lipid mixture (Figure 2.2). Liposomes formed in the absence of PEG 
were found to exhibit an inverse relationship between FRR and liposome diameter, as shown in 
Figure 2.3. The error bars in this figure reflect the FWHM distribution of each liposome 
population. This figure also reveals a very similar behavior for PLs formed at both 
concentrations of PEG5000 explored in this study. The liposome populations produced by the 
microfluidic flow focusing method do not significantly change with PEG5000-lipid 
concentration, but remain largely controlled by the flow conditions used in the focusing process. 
This is not necessarily an expected outcome considering the roles of hydrodynamics and 
diffusion in the liposome formation process.
44
 The average on-chip residence time in these 
studies was only 250 ms, and liposome formation likely occurs within an even shorter time 
during the initial mixing zone at the confluence of the lipid and aqueous streams. Given that 
PEG5000 is approximately eight times the molecular weight of the native lipids used in the 
initial mixture, differences in diffusive transport for the PEG-modified lipids as well as steric 
hindrance during the self-assembly process could be expected to affect the liposome formation 
process. The data presented in Figure 2.2 and Figure 2.3 reveals that the microfluidic process 




inclusion of PEG-modified lipids. Similarly, no significant variation in liposome size distribution 
is observed.  
As revealed in Figure 2.4, zeta potential was found to be directly correlated with liposome 
radius, with the strength of this correlation depending on PEG-PE concentration. This latter 
observation may result from reduced steric interactions between PEG chains for higher curvature 
vesicles,
103
 encouraging preferential incorporation of PEG-PE into smaller liposomes and 
concomitant increase in charge shielding. Additionally, the shielding effect PEG on the liposome 
is greater at 10 mol % PEG-PE than at 5 mol % PEG-PE. The greater degree of observed charge 
shielding at each liposome size for the 10 mol % PEG-PE liposomes may be due to the 
anticipated formation of a brush configuration at this high PEG concentration, Although further 
characterization is needed to verify this hypothesis, surface-grafted PEG molecules are known to 
prefer a tightly packed brush configuration resulting in extension of the linear PEG chains at 
high surface concentrations, while a more loosely arranged mushroom or transition regime 
occurs at lower concentrations.
104
 Overall, the inverse correlation between zeta potential and 
PEG-PE content reveals that the PEG-conjugated lipids are effectively incorporated into the 
liposomes using the microfluidic flow focusing process. The incorporation of PEG-lipids was 
further confirmed by UV-vis absorbance analysis (Figure 2.5), with the resulting data consistent 
with the hypothesis that incorporation of PEG-PE lipids is favored during interactions with 
higher curvature membranes, and thus are more readily incorporated into smaller liposomes. 
Cryo-TEM imaging was performed to ensure that the presence of large PEG molecules did 
not affect vesicle unilamellarity. The imaging results shown in Figure 2.6 reveal a spherical 
morphology and overall agreement in size compared to the size information obtained from light 
scattering. PEGylated liposomes and control liposomes appear similar size and shape. While 




surfactants due to insufficient electron density,
105
 the data confirms that unilamellar liposomes 
are formed in both cases, with an average membrane thickness of 5.4 ± 0.6 nm  corresponding to 
the expected bilayer membrane thickness of DMPC in water.
106
 Lipid bilayer thickness was 
determined using the scale bar provided by the TEM instrument, with each reported value 
reflecting the average from 4 measurements performed on 4 individual liposomes. 
Figure 2.7 shows the concentration of folate on FPLs from values obtained via the UV-vis 
absorption spectroscopy. The integrated values for folate are largely in agreement with the 
expected folate content, indicating successful inclusion of PEG2000-Fol-PEinto the FPLs at 
approximately the same molar ratio of folate-conjugated lipids in the initial lipid mixture. The 
larger FPLs with diameters above 100 nm, corresponding to FRRs of 40 and 70, exhibited folate 
concentrations slightly above the initial mixture concentration. While the measured folate 
concentration in the smaller FPLs was only 60% of the initial molar ratio, this may be due to the 
reduced liposome concentration associated with the high FRR value of 100 used to form these 
FPLs, resulting in absorbance signals near the detection limit of the UV-vis spectrometer. Thus, 
while all of the liposomes exhibited clear evidence of folate incorporation, the high level of 
uncertainty in the absorbance data for the smallest liposomes does not support a conclusion that 
the final concentration of folate is related to liposome size. 
Application of the microfluidic technique to liposomal drug preparation will require scale-up 
of the technology for the production of large liposome volumes at concentrations suitable for in 
vivo use. Ultimately, a dense array of individual flow focusing elements fabricated on a single 10 
cm square thermoplastic chip could be implemented, with on-chip flow splitters used to control 
the delivery of solvent, buffers, and functional reagents to the parallel flow focusing channels. Of 
the parameters known to have a direct impact on liposome size, including channel geometry, 




Photolithographic control of the imprinting mold used for channel fabrication can ensure uniform 
hydrodynamic resistance across the microchannel array, and thus uniform flow rates and FRR 
values for precise and reliable control over liposome size during process scale-up.  
2.6 Conclusion 
This chapter demonstrates the successful extension of microfluidic-directed liposome 
formation technology to include the continuous, controlled synthesis of nearly monodisperse 
populations of PEG-modified and folate receptor-targeted liposomes. Liposomes comprised of 
DMPC and cholesterol with varying compositions of PEG5000-lipids, PEG2000-lipids, and folate-
PEG2000 lipids have been successfully formed using a thermoplastic microfluidic chip enabling 
adjustable hydrodynamic focusing of a stream of lipids dissolved in an organic solvent by 
miscible streams of an aqueous buffer. Despite the large difference in molecular weight between 
the native lipids explored in previous studies and the PEG-lipid and folate-PEG-lipid conjugates 
used in this chapter, no significant difference in liposome size or size distribution was observed 
between these two cases. This technique opens doors for a variety of liposome applications, such 
as the ability to provide PEG-modified liposomes and folate-targeted liposomes with tunable 
characteristics and lipid compositions for targeted drug delivery. Further, the ability to achieve 
rapid, one-step synthesis of functionalized, unilamellar liposomes has great potential for further 
development toward the realization of on-chip liposome “microfactories” wherein liposome 
formation, liposome functionalization, and drug encapsulation is performed with real-time 




 : Microfluidic Remote Loading for Rapid Single-Step Chapter 3
Liposomal Drug Preparation 
3.1 Summary 
 Microfluidic-directed formation of liposomes is combined with in-line sample purification 
and remote drug loading for single step, continuous flow synthesis of small, nearly monodisperse 
vesicles containing high concentrations of stably loaded drug compounds. Using microfluidic 
buffer exchange within an on-chip microdialysis zone, the system enables the rapid formation of 
large transmembrane pH and ion gradients, followed by the immediate introduction of 
amphipathic drug for remote loading into the vesicles. The result is a microfluidic process 
enabling in-line formation of liposomes containing remotely loaded compounds at drug:lipid 
molar ratios of up to 1.3 with a total on-chip residence time of approximately 3 min, representing 
a significant improvement over conventional bulk scale methods which require hours to days for 
combined liposome synthesis and remote drug loading. The microfluidic platform may be further 
optimized to support real-time generation of purified liposomal drug formulations with high 
concentrations of drugs and minimal reagent waste for effective liposomal drug preparation at or 
near the point of care. 
3.2 Introduction 
An important feature for the enhanced clinical utility of liposomal drugs has been the 
development of effective methods for loading high concentrations of therapeutic compounds into 
lipid vesicles. Strategies for encapsulation of drugs into liposomes may be categorized as either 
passive or active. Passive encapsulation is inefficient,
15
 provides limited attainable drug-to-lipid 
ratios (D/Ls) due to drug solubility,
107




are able to migrate out of the vesicles over time.
108
 In contrast, active encapsulation (remote 
loading) results in stable formulations of liposomes with a high D/L. Because in vivo toxicity is 
inversely related to D/L,
61
 increased drug concentration is a highly desirable attribute for 
nanoparticle-enabled therapeutics. 
A microfluidic system that enables rapid and efficient remote loading of amphipathic drugs 
into nanoscale liposomes is reported in this chapter, combining liposome synthesis and remote 
drug loading in a seamless integrated process. Unlike established bulk methods for remote drug 
Figure 3.1: (a) Schematic of the fully-integrated microfluidic device for remote loading 
of liposomal therapeutic nanomedicines in-line with liposome synthesis and buffer 
exchange via microdialysis for rapid generation of nearly monodisperse, functionalized 
liposomes with tunable diameters containing high concentrations of stably loaded 
compounds. (b) Cross-sectional view of the microfluidic system, revealing the differing 





loading, in which each process step is performed in a series of discrete manual operations using 
large fluid volumes, the microfluidic system incorporates liposome formation, buffer exchange, 
and liposome/drug mixing and incubation in a continuous flow process. The platform (Figure 
3.1) takes advantage of an established microfluidic hydrodynamic flow focusing method for the 
formation of functionalized, nearly monodisperse liposomes.
41–44,86
 The liposome synthesis 
technology is extended in this chapter with the addition of a counterflow microdialysis element, 
enabling steep transmembrane ion gradients to be formed immediately prior to remote drug 
loading. The system further implements a drug loading and incubation zone that includes 
micromixer structures to enhance interactions between liposomes and amphipathic compounds 
during the remote loading process. The resulting device decreases the processing time for 
liposome preparation and remote drug loading from a multi-day process to less than 3 minutes, 
with resulting D/L values up to 5 times greater than typical liposomal therapeutics prepared by 
conventional bulk scale processes.
109
 
3.3 Materials and Methods 
3.3.1 Device Fabrication 
Microchannels were fabricated in polydimethylsiloxane (PDMS) substrates by soft 
lithography techniques using dry film photoresist molds
110
 produced in a multilayer lamination 
process. Dry film photoresist (Riston MM115i, DuPont, Research Triangle Park, NC) was 
laminated onto a clean glass slide at 110 °C using a feed rate of 0.02 m/s and placed on a hot 
plate at 110 °C for 20 min to promote adhesion. The substrate was patterned by contact 
photolithography using an ultraviolet (UV) flood exposure instrument (PRX-1000; Tamarack 
Scientific Co., Corona, CA) at a dose of 72 mJ/cm
2
 for a single layer of photoresist. Multiple 




dose per layer. Each layer of the dry film photoresist is approximately 37 µm, as measured using 
by stylus profilometry. Following UV exposure, the multilayer substrate was developed using a 1 
wt% sodium carbonate solution. The resulting molds feature 3 regions with 3 different channel 
heights (Figure 3.1). Specifically, the flow focusing and liposome stabilization region was 30 
µm wide and 112 µm deep, the buffer exchange region was 1.2 mm wide and 37 µm deep, and 
the drug loading and mixing region was 30 µm wide and 77 µm deep. Buffer counterflow 
channels were 1.2 mm wide and 37 µm deep. 
The dry film photoresist molds were next used to create microchannels in PDMS. Two 
separate molds were used to form an upper substrate containing flow focusing, buffer exchange, 
and drug loading channels, and a lower substrate containing a buffer counterflow channel to 
assist in microdialysis. The molds were placed in plastic petri dishes and a 10:1 (w:w) mixture of 
pre-polymer PDMS elastomer and curing agent (Sylgard 184, Dow Corning Corp. Midland, MI) 
was poured on top. Vacuum was applied to remove air bubbles, and the petri dish was placed in a 
convection oven at 80 ºC for 4 h to ensure complete curing of the PDMS. The PDMS substrates 
were removed from the molds and sectioned using a fresh scalpel. Holes for inlet and outlet 
interfacing were made using a microbore biopsy punch (Harris Uni-Core, Ted Pella, Inc., 
Redding, CA). All PDMS surfaces were cleaned with isopropanol and DI water. 
To form the microdialysis elements, 12-14 kDa molecular weight (MW) cutoff regenerated 
cellulose (RC) membranes Spectra/Por 4, Spectrum Laboratories Inc., Rancho Dominguez, CA) 
were placed between the upper and lower PDMS substrates. The membranes were selected to 
ensure that the nominal pore size (<4 nm)
111
 is below the minimum liposome size but large 
enough to allow all individual chemical species and buffer salts to transport efficiently through 
the membrane. The RC membranes were cut into patterns similar to the microchannel geometries 




Orem, UT), allowing space between adjacent channels for direct PDMS-PDMS contact in these 
regions. The patterned membranes were flattened using a hydraulic hot press (Carver, Wabash, 
IN) at 0.7 MPa for 10 min at 110 ºC prior to chip integration. To enhance sealing between the 
PDMS substrates, a 10:1 (w:w) mixture of pre-polymer PDMS elastomer and curing agent was 
poured over a glass slide and spin coated at 3500 rpm for 60 s. The bottom piece of PDMS 
containing the counterflow channels was stamped onto the thin layer of PDMS, which served as 
a sealing agent for the microchannels. The patterned RC membrane was aligned with the 
microchannels on the top piece of PDMS containing the flow focusing, dialysis, and drug 
Figure 3.2: Schematic (exploded view) (a-c) of the PDMS/cellulose hybrid microfluidic 
device with a) a channel for buffer counterflow b) patterned nanoporous regenerated 
cellulose dialysis membrane, and c) sample channel for liposome synthesis, buffer 




loading regions. The two substrates were aligned and pressed together by hand, then placed in a 
convection oven at 80 ºC overnight to cure the intermediate PDMS bonding layer. Figure 3.2 
represents a schematic of an exploded view of the device components as well as a photograph of 
the actual device.  
3.3.2 Lipid Mixture and Hydration Buffer Preparation 
Lipid mixture preparation and hydration buffer were prepared as previously described 
(Chapter 2.3.2, p. 21). Briefly, DMPC, cholesterol, and PEG2000-PE were combined in 
chloroform at a molar ratio of 55:35:10. The lipid mixture was desiccated under vacuum then re-
dissolved in anhydrous ethanol for a total lipid concentration of either 40 mM or 20 mM, as 
noted. 
Ammonium sulfate (250 mM, adjusted to pH 4.6) and isosmotic HEPES (10 mM with 140 
mM sodium chloride, adjusted to pH 7.6) were prepared for microdialysis and remote loading 
experiments. In some cases, trisodium 8-hydroxypyrene-1,3,6-trisulfonate (pyranine) 
(Invitrogen) was added to the buffers for pH measurements (1 µM). Acridine Orange 
hydrochloride (AO) at an initial concentration of 10 mg/mL (Sigma-Aldrich) was further diluted 
in deionized water as noted and used for remote loading experiments. Doxorubicin hydrochloride 
(DOX) (Sigma-Aldrich) was diluted to 1.4 mg/mL for in-line synthesis and remote loading 
experiments. All solvents and buffers were passed through 0.22 μm filters before being 
introduced to the microfluidic device. 
3.3.3 Buffer Exchange and Remote Drug Loading 
Microfluidic devices comprising only the 27 cm long buffer exchange zone (sample channel 
and buffer counterflow channel) were first used to characterize performance of the microdialysis 




ammonium sulfate (pH 4.6) was injected into the sample inlet and isosmotic HEPES (pH 7.6 or 
pH 9.6) was injected into the buffer counterflow inlet with the resulting sample collected for 
analysis. Sample and counterflow flow velocities were kept equal to one another, and varied 
from 0.3 cm/s to 0.6 cm/s (approximately 7 µL/min to 14 µL/min, respectively). Pyranine was 
used as a pH-sensitive molecular probe to determine the pH of the sample and counterflow 
buffer eluents. Fluorescence intensity maxima of pyranine at 400 nm and 450 nm is strongly 
dependent on hydrogen ion concentration, and thus measuring the ratio of the 510 nm 
fluorescence signal at these excitation wavelengths allows solution pH to be determined.
112
 Off-
chip samples as well as standard curves for calibration over the range from pH 3 to pH 12 were 
measured using a SpectraMax plate reader (Molecular Devices, Sunnyvale, CA). 
To assess the remote drug loading process following buffer exchange, liposomes were first 
prepared in a separate microfluidic chip by hydrodynamic flow focusing.
41–44
 Briefly, hybrid 
PDMS-glass devices with 50 µm wide and 300 µm deep microchannels were fabricated, and 
lipid-ethanol mixture (40 mM) was injected into the microfluidic device between two sheath 
flows of ammonium sulfate buffer (250 mM, pH 4.6). The flow rate ratio, defined as the ratio of 
the volumetric flow rate of the aqueous buffer to the flow rate of lipids in ethanol,
41–44
 was set to 
20. Total linear flow velocity was set to 12.5 cm/s, or an equivalent volumetric flow rate of 112 
µL/min. To reduce vesicle size, the microfluidic device was operated on a hot plate at 50 °C 
throughout synthesis.
93
 The resulting liposome size distributions were characterized via dynamic 
light scattering (Nano ZSP, Malvern Instruments Ltd., UK).  
The liposomes in ammonium sulfate buffer were injected into the inlet of the microdialysis 
chip with isosmotic HEPES (pH 7.6) as the buffer counterflow. AO, an amphipathic dye used as 
a drug analog for remote loading experiments, was introduced through a secondary channel 




flow rate. Liposome sample velocity was varied from 0.17 cm/s to 0.44 cm/s with AO 
concentration constant at 0.25 mg/mL to investigate the effect of flow velocity and residence 
time on loading concentration and efficiency. AO concentration was varied from 0.125 mg/mL 
to 2.5 mg/mL (corresponding to D/L values of 0.22 to 4.35, respectively) with the flow velocity 
held constant at 0.26 cm/s to explore the effect of AO concentration on loading efficiency and 
maximum D/L levels in the resulting drug-laden liposomes. 
To analyze AO concentrations, liposome samples were collected following AO loading and 
placed into 7 kDa MW cutoff dialysis units (Slide-A-Lyzer MINI; Pierce, Rockford, IL) with 
isosmotic HEPES as the exchange buffer. The samples were dialyzed for 4 h with 3 buffer 
exchanges to ensure complete purification of free AO. Absorbance measurements of the purified 
samples as well as a serial dilution of AO in buffer at λmax=495 nm were taken using a plate 
reader (SpectraMax; Molecular Devices, Sunnyvale, CA) to determine encapsulated AO 
concentration. 
3.3.4 Numerical Simulation of Ion Exchange via Microdialysis 
Exchange of ammonium sulfate ions during microdialysis was investigated via numerical 
simulations with a two-dimensional model using COMSOL Multiphysics 4.1 (COMSOL, Inc., 
Burlington, MA). The Transport of Diluted Species (chds) physics interface was applied for the 
simulation to depict the concentration profiles of the ammonium sulfate salt within the 
microchannels. Microchannel dimensions from the actual devices fabricated and RC membranes 
used for the study were used to build the model, as well as the known value of the diffusion 











3.3.5 In-Line Liposome Synthesis and Drug Loading 
An integrated device containing a liposome formation region, microdialysis buffer exchange 
region, and drug loading region was used to evaluate the overall process. For liposome 
formation, lipid-ethanol solution (20 mM) was injected into the flow focusing element between 
two sheath flows of aqueous ammonium sulfate buffer (250 mM, pH 4.6). The total volumetric 
flow rate was 6 µL/min (corresponding to 0.26 cm/s in the dialysis region) with a flow rate ratio 
of 10. The microdialysis counterflow buffer flow rate was matched to the primary flow rate to 
minimize the average pressure gradient across the RC membrane. The drug:liposome sample 
flow rate ratio was 1:3 for all experiments. For drug loading, both AO (0.5 mg/mL and 1.0 
mg/mL, corresponding to initial D/L values of 0.22 and 0.44, respectively) and DOX (1.4 
mg/mL, corresponding to an initial D/L of 0.44) were investigated. Multiple samples were 
collected (n=3) for each test. 
To ensure that free drug remaining in the collection buffer following remote loading did not 
affect concentration measurements, collected liposome samples were further dialyzed off-chip 
with isosmotic HEPES as the exchange buffer. Two aliquots of each sample, one off-chip and 
one two-fold dilution, were dialyzed for 4 h with 3 buffer exchanges for complete purification of 
free DOX or AO. Absorbance measurements of the purified samples as well as a serial dilution 
of DOX or AO in buffer were compared with standard curves to determine final encapsulated 
drug concentration. Size distributions of collected samples were further characterized by 





3.4 Results and Discussion 
3.4.1 Counterflow Microdialysis for Buffer Exchange 
Counterflow microdialysis provides an efficient method for on-chip buffer exchange, 
enabling rapid transport and removal of free ions from the sample buffer while preventing loss of 
nanoparticles during the exchange of small ions across the microdialysis membrane. To evaluate 
performance of this approach for establishing transmembrane ion gradients prior to remote drug 
loading in a rapid flow-through format, a PDMS-RC device consisting solely of the counterflow 
microdialysis zone was fabricated. Characterization of the device for ion exchange was first 
evaluated by introducing buffers at different pH values through the sample and counterflow 
ports. Rapid pH change of the sample flow was observed, as revealed through pyranine 
Figure 3.3: Demonstration of on-chip microfluidic buffer exchange via membrane 
dialysis at various counterflow pH and flow velocities. Residence times vary from 40 s to 
80 s, resulting in a ΔpH 1.7 to 3.0. Total flow rates vary approximately 7 µL/min to 14 




fluorescence measurements, with the level of pH shift roughly proportional to residence time as 
determined by the applied flow rate (Figure 3.3). As expected, microdialysis performance was 
also found to be dependent on counterflow buffer pH, with a greater difference in pH between 
the sample and counterflow buffers resulting in a larger pH shift at the sample buffer outlet. For 
the experimental conditions tested, a maximum shift of 3 pH units was achieved using pH 9.6 
counterflow buffer and a residence time within the dialysis channel of 83 s. This is substantially 
faster than bulk scale microdialysis which can take hours for complete buffer exchange to occur.  
A prediction for the transport of ammonium sulfate ions during microdialysis can be made by 





/s for the diffusion coefficient of ammonium sulfate in water at room temperature,
113
 the 
diffusion time for a characteristic length scale given by the microchannel height (37 µm) is 1.71 
Figure 3.4: Numerical simulation of ammonium sulfate (initial concentration 250 mM) 
transport in the microfluidic device to verify adequate ion removal: a) depiction of the 
ammonium sulfate concentration throughout the microdialysis segment of the device 
(channel length scaled by a factor of 10 for more rapid computation), and b) 
concentration profile of ammonium sulfate along the sample channel, RC membrane, and 
counterflow channel at the exit of the dialysis region for flow velocities varying from 0.3 




s, significantly smaller than the residence times explored in these studies which ranged from 42 s 
to 83 s, To verify this prediction, ammonium ion transport was evaluated through a two-
dimensional numerical simulation of the device. As shown in Figure 3.4, the model suggests that 
the extra-liposomal ammonium ion content is reduced by more than 100 times from the initial 




A potential concern with the continuous flow microdialysis element is whether liposome size 
is affected by the process. Prior to buffer exchange, the microfluidic-synthesized liposomes were 
found to be 80.8 nm in diameter with a very low polydispersity index (PDI) of 0.049. Size 
distributions measured before and after on-chip microdialysis revealed only a slight increase in 
mean vesicle size to 91.5 nm, confirming that the on-chip counterflow microdialysis element did 
not significantly affect the liposome size. Buffer counterflow eluent was also collected and 
examined via light scattering. No detectable signal was observed, revealing that intact liposomes 
do not escape the membrane and enter the counterflow during microdialysis.  
3.4.2 On-Chip Remote Drug Loading 
Anthracyclines represent an important class of drugs for liposomal encapsulation. Received 
by nearly every patient undergoing systemic cancer chemotherapy, anthracyclines are among the 
most utilized and effective antitumor drugs developed to date.
115
 Liposomal forms of 
anthracyclines can provide increased efficacy with significantly reduced toxicity,
116
 enhancing 
the overall clinical value of the drugs.
117
 Liposomal encapsulation of the anthracycline 
doxorubicin has proven particularly successful for treatment of a range of cancers, with remote 
loading of DOX into preformed liposomes being a key to this success.
114
 Here, DOX is used as a 
model drug encapsulant to investigate the potential for continuous flow remote drug loading 




Initial testing was performed using preformed liposomes injected into the counterflow 
microdialysis chip to form the desired transmembrane ion gradient, followed by on-chip 
introduction of AO as a suitable analog to DOX. AO is an amphipathic weak base with similar 
properties to DOX, and is known to behave similarly to DOX during remote loading with 
ammonium sulfate gradients.
60,118–120
 Figure 3.5a presents the measured final D/L and 
encapsulation efficiency (EE) for AO-loaded liposomes prepared using an initial D/L of 0.44 
when varying the sample velocity from 0.18 cm/s to 0.45 cm/s, for a total residence time within 
the mixing channel ranging from 4.25 min to 1.7 min, respectively. While a slight increase in 
both final D/L and EE was observed with increasing flow rate, overall remote loading using the 
microfluidic approach exhibited little dependence on flow velocity. In contrast, the initial 
concentration of drug compound introduced following ion exchange had a substantial effect on 
the final D/L (Figure 3.5b). By increasing the initial D/L level, final D/L values up to 1.3 were 
achieved. This effect is likely due to the significantly decreased diffusion lengths with increasing 
AO concentration and thus a greater quantity of AO may be loaded when the initial 
Figure 3.5: Relationships of (a) sample velocity and (b) initial AO concentration on final 
encapsulated concentration and loading efficiency. Microfluidic-generated liposomes, 




concentration is higher. Reported D/L values for liposomal anthracyclines produced via 
conventional bulk scale remote loading are typically below 0.25,
109
  significantly less than the 
levels achieved using the microfluidic process. This phenomenon is likely due to the rapid buffer 
exchange followed by AO introduction, the high initial D/L ratio, or a combination of the two.  
Encapsulation efficiency of the resulting liposomes was observed to increase with initial D/L, 
and then began to diminish for initial D/L values exceeding 2.17. This result is in accordance 
with previous studies based on bulk scale loading based on longer loading periods (hours to 
days), which suggest EE peaks at an initial D/L of 0.95 and decreases at higher ratios.
120
 This 
behavior is due to insufficient intravesicular loading capacity above some limiting D/L level, 
resulting in a lower EE as drug concentration is further increased. The higher optimal D/L 
observed for the microfluidic platform is believed to result from the highly efficient formation of 
a transmembrane ion gradient due to rapid microfluidic buffer exchange, together with 
immediate interactions between the vesicles and the amphipathic molecules to be loaded. The 
steep transmembrane ion gradient achieved through rapid buffer exchange may enable higher 
D/L ratios to be achieved through microfluidic remote loading versus bulk scale processes. 
To achieve remote loading through a transmembrane ion gradient, buffer exchange must 
occur prior to incubation with the drug to remove the loading salts from the exterior environment 
while simultaneously adjusting the carrier buffer to physiological pH. Because the 
transmembrane ion/pH gradient is transient, loading efficiency can be improved by decreasing 
the time between establishing the gradient and drug incubation.
121
 Thus, if the amount of total 
ammonium sulfate ions are present in identical microfluidic versus bulk scale buffer exchanges, 
a higher ratio of the ions is likely to be present within the core of the liposomes versus the 
amount which have permeated through the membrane into the extra-liposomal space for the 




drug/agent. Although typical D/L values of commercially available liposomal anthracyclines 
range from 0.125 to 0.250,
109
 it has been shown that the behavior of amphipathic molecules 
during remote loading is highly dependent on environmental conditions,
120
 with D/L as high as 
1.7 obtained under ideal loading conditions (i.e. higher residual pH gradients and optimized D/L 
ratios and ionic concentrations).
122
 However, liposomes generated through bulk manufacturing 
processes rarely approach this range, presumably due to limitations with maintaining steep 
transmembrane gradients during the relatively long drug diffusion time scales inherent to bulk 
scale processing, non-uniform distributions of the drug within the bulk fluid, or increased 
diffusion lengths after the initial loading period where adjacent drug is rapidly loaded into the 
liposomes. Microfluidic remote loading enables rapid buffer exchange for steeper pH and ion 
gradients together with microscale, homogeneous mixing for decreased diffusion lengths during 
drug loading, thus providing a more efficient method for drug loading in order to achieve higher 
final D/L ratios in the resulting populations of liposomes. 
3.4.3 In-Line Liposome Synthesis and Remote Drug Loading  
After demonstrating buffer exchange, pH adjustment, and remote loading of AO into 
preformed vesicles using the microfluidic approach, liposome synthesis in-line with 
microdialysis and remote loading of both AO and DOX was performed using an integrated 
device combining all of the process steps in a single flow-through chip. The resulting liposomes 
were first characterized for diameter (volume-weighted) when AO, DOX or buffer was 
alternately injected as the drug loading phase (Figure 3.6). Under the flow conditions used in 
these experiments, the resulting liposomes exhibited an average diameter of 225.5 nm ± 44.8 nm 
for the case of buffer without amphipathic encapsulant, while a reduction in liposome size to 
190.9 nm ± 43.0 nm for DOX-loaded liposomes and 191.5 nm ± 33.4 nm for AO-loaded 




loading may reflect a change in morphology to a characteristic “coffee bean” resulting from drug 
aggregation within the vesicles,
59
 leading to altered signals during dynamic light scattering. 
Confirmation of drug crystallization was verified through cryogenic transmission electron 
microscopy (cryoTEM) imaging (Figure 3.6). 
A summary of measured final D/L values following AO and DOX loading within the 
integrated microfluidic device is presented in Table 3.1.  Prior results for the case of AO loading 
using preformed liposomes generated in a separate chip are also shown for comparison. An 
initial D/L of 0.44 was selected for DOX, as this ratio was found to maximize loading efficiency 
in initial experiments using AO (Figure 3.4). The DOX loaded liposomes generated by the 
microfluidic device had a final D/L of 0.32 ± 0.03, which exceeds the typical D/L of 0.25 or less 
Figure 3.6: Volume-weighted size distributions from remote loading of DOX and AO 
into liposomes in-line with synthesis and microdialysis for buffer exchange in 




achieved by bulk remote loading employing overnight incubation.
59
 The total on-chip residence 
time of within the microfluidic device was less than 3 min. In addition, initial D/L values of 0.22 
and 0.44 were used for testing AO loading, resulting in final D/L values of 0.06 ± 0.01 and 0.32  
±  0.11, respectively.  
Encapsulation efficiency using the integrated system was also evaluated. Referring to Table 
3.1, the DOX-loaded liposomes yielded an EE of approximately 72%, lower than typical values 
for conventional remote loading which can exceed 99%.
121
 Lower encapsulation efficiency 
compared to bulk scale remote loading is not surprising, since the incubation time is up to 300 
times lower within the microfluidic system. Regardless, this is an aspect of the microfluidic 
approach which must be improved to minimize drug waste, for example by implementing a 
method for capturing and recycling drug in an additional on-chip stage following remote loading. 
In addition to reducing manufacturing costs by reducing waste of valuable drug compounds, 
optimizing loading conditions could also eliminate the need for off-chip purification, enabling 
real-time production of stably encapsulated, highly concentrated liposomal drugs at or near the 
point of care.  
Table 3.1: Summary of D/L and EE measurements for AO loaded liposomes (preformed 
liposomes produced in a separate chip) and DOX and AO loaded liposomes (formed in-
line with synthesis in a single integrated chip). Similar results were achieved for DOX 
and AO loading within the integrated device. Slightly higher final D/L and EE values 




Direct comparison of in-line system performance with the previous results from remote 
loading using preformed liposomes is hampered by the different sizes of each liposome 
population. When performing in-line remote loading, fluidic coupling between the upstream 
liposome formation zone and downstream microdialysis and drug loading zones demands careful 
design of the channel dimensions, together with appropriate selection of inlet flow rates. 
Liposome size and polydispersity are both impacted by the buffer:lipid flow rate ratio, overall 
volumetric flow rate, and microchannel dimensions selected for effective liposome self-assembly 
during hydrodynamic flow focusing.
41–44,86
 However, these same parameters also affect 
microdialysis and remote drug loading performance. While channel dimensions for each 
functional element in the system can be designed independently, allowing a degree of decoupling 
between these constraints, the current microfabrication process used for device manufacture 
presents some limitations. For example, to avoid sagging of the microdialysis membrane, a 
maximum channel width of 1.2 mm was used for the buffer exchange zone. Similarly, total 
volumetric flow rates were minimized to prevent delamination of the hybrid microfluidic device 
due to excessive internal fluid pressure. As a result of these constraints, liposomes formed using 
the on-line system were approximately twice the diameter of their preformed counterparts. 
Although residual pH gradients decrease with decreasing vesicle size due to decreased 
intravesicular volumes, it has been shown that this effect can be circumvented by including a 
buffering capacity greater than 300 mM.
122
  Additionally, given the significantly larger volume 
of the in-line liposomes, it is notable that both the final D/L and EE values for in-line 
encapsulation were comparable to the case of preformed liposome loading, with slight increases 
in both values for the larger liposomes. This further emphasizes the observation that the initial 
D/L is the dominant parameter that defines encapsulation performance during remote loading 





By combining liposome synthesis via microfluidic flow focusing, membrane microdialysis 
for buffer exchange and in-line introduction of amphipathic weak bases for remote loading 
within a single microfluidic device, this study converts a conventional multi-step bulk scale 
process requiring hours to days of labor into a microscale process which requires a total on-chip 
residence time of approximately 3 minutes. By taking advantage of the reduced diffusive length 
scales characteristic of microscale flows, the microfluidic method implements remote loading as 
a seamless continuous flow process, with the potential to simplify and increase the robustness of 
this critical step in nanoliposomal drug production. The further ability to perform integrated 
liposome formation using hydrodynamic flow focusing prior to formation of a transmembrane 
ion gradient for remote drug loading allows the entire sequence of steps required for liposomal 
drug production to be performed as a single in-line and continuous flow process. The 
microfluidic method demonstrated here enables exceptionally high drug loading levels, with D/L 
values above unity easily achieved. Future optimization of device design and flow conditions are 
expected to further improve encapsulation efficiency, enabling just-in-time production of 




 : Synthesis of Nearly Monodisperse Nanoscale Liposomes Chapter 4
Using 3D Microfluidic Hydrodynamic Focusing in a Concentric 
Capillary Array 
4.1 Summary 
A novel microscale device has been developed to enable the one-step continuous flow 
assembly of nearly monodisperse nanoscale liposomes using three-dimensional microfluidic 
hydrodynamic focusing (3D-MHF) in a radially symmetric capillary array. The 3D-MHF flow 
technique displays patent advantages over conventional methods for nanoscale liposome 
synthesis (i.e. bulk scale alcohol injection and film hydration and extrusion) through the on-
demand manufacture of consistently uniform liposomes at unparalleled rates (factor of 10
4
 
liposomes/min increase in production rate relative to state-of-the-art liposome production 
strategies). Liposomes produced by the 3D-MHF device are of tunable size and have a factor of 
two improvement in polydispersity over previous MHF methods which can be attributed to 
entirely radially symmetric diffusion of alcohol-solubilized lipid into an aqueous flow stream. 
Moreover, the 3D-MHF platform is simple to construct from low-cost, commercial parts, which 
obviates the need for advanced microfabrication strategies necessitated by previous MHF 
nanoparticle synthesis platforms.  
4.2 Introduction 
Several approaches for liposome synthesis have been investigated to improve upon 
conventional manufacture shortcomings; however, few have effectively demonstrated delivery of 
an on-demand clinically reliable product of sufficient throughput.
7 
Incremental advancements in 




microfluidic hydrodynamic focusing (MHF), a technique that enables the one-step continuous 
flow production of nearly monodisperse, nanoscale, unilamellar vesicles using two-dimensional 
(2D) flow focusing in rectangular microchannels.
41–44
 It has been demonstrated that MHF can 
produce liposome populations that are consistently more uniform than the preparations of 
liposomes resulting from conventional manufacture strategies. Additionally, size control of 
vesicle preparations formed using MHF can be precisely tuned and easily automated using pre-
programmed computer controlled flow inputs.
13
  
Applying the benefits of liposome synthesis provided by MHF towards the widespread 
commercial manufacture of liposomes are known to be limited by several practical aspects of the 
technique including: (i) inherent drag forces that affect symmetric flow focusing in rectangular 
microchannels, (ii) low throughput due to characteristically low microfluidic flow rates, and (iii) 
expensive, time-consuming microfabrication techniques necessary to develop the liposome 
manufacture devices. Here, an attempt is made to ameliorate these practical short comings of 
MHF for liposome production by extending application of the technique to a facile, cost-
effective annular coaxial flow system. The microfluidic coaxial flow system described is 
composed of an array of commercially available capillaries that enables three-dimensional fluid 
focusing for liposome synthesis. In comparison, previously demonstrated 2D-MHF strategies in 
planar devices only focus the solvated lipid stream in the lateral dimension.  Further, the 
horizontal surfaces of the planar microfluidic devices are wetted with the organic lipidic stream 
(with a no-slip boundary condition), causing lipidic fluid further away from the channel center to 
convect more slowly through the fluidic channel. Although various strategies for three-
dimensional hydrodynamic focusing have been demonstrated,
123–125
 these processes involve 
piece-wise, rectangular focusing and the sample flow is not focused until a point farther 




immediately after the initial ethanol-water interface is formed;
44
 thus immediate hydrodynamic 
focusing in addition to complete radial symmetry through a coaxial flow system is a necessity. In 
the coaxial flow system, there are no surfaces in the mixing region wetted by the lipidic organic 
phase and thus no lipid fluid elements are subjected to the no-slip boundary condition.  
Therefore, the 3D-MHF strategy for liposome preparation maintains technical advantages over 
previously investigated 2D-MHF strategies as the annular flow geometry enables complete 
radially symmetric mixing of the fluidic inputs allowing for a more uniformly consistent product. 
As a result, nearly monodisperse liposomes can be manufactured at unparalleled rates with 
precise size control. 
4.3 Materials and Methods 
4.3.1 Device Fabrication 
Concentric capillary devices were assembled from a stock seven-barrel glass capillary 
(World Precision Instruments, Sarasota, FL) (Figure 4.1). The multibarrel capillary contains 
seven identical borosilicate glass capillaries which individually have an inner diameter (ID) of 
0.58 mm and outer diameter (OD) of 1.0 mm and are arranged in a circular pattern with an 
equivalent outer diameter of 3 mm. The multibarrel capillary array is 152 mm in length, but can 
be sectioned into smaller pieces for a smaller device assembly. Poly(ether ether ketone) 
(PEEK
TM
) tubing (510 µm OD, 65 µm ID) unless otherwise specified) (Upchurch Scientific, 
Inc., Oak Harbor, WA) served as the solubilized lipid feed line and was threaded through the 
center of the multicapillary array. The lipid feed line was connected through minitight fittings 
(Upchurch Scientific, Inc.) to a glass Gastight® syringe (Hamilton, Reno, NV) that delivered the 
lipid solution. The solubilized lipid infusion was controlled by a programmable syringe pump 




Co., Veron Hills, IL) was used as the support line for the extra-annular aqueous sheathing flow. 
A continuous supply of aqueous sheath flow was supplied by a quaternary pump (Agilent 
Technologies, Santa Clara, CA) at programmable volumetric flow rates. The junction between 
the lipid feed line and multicapillary device was sealed on the downstream end using UV-curable 
epoxy (NOA81) (Norland Products Inc., New Brunswick, NJ). 
Figure 4.1: Schematic of the 3D-MHF annular flow liposome formation device. Narrow 
bore capillary tubing is secured by a glass multicapillary array which serves to precisely 
center the intra-annular flow stream in the concentric exterior coaxial flow stream. For 
liposome synthesis, an alcohol-solubilized lipid solution is continuously injected into the 
intra-annular capillary tubing and hydrodynamically focused in three-dimensions by an 





4.3.2 Lipid Mixture and Hydration Buffer Preparation 
Lipid mixture preparation and hydration buffer were prepared as previously described 
(Chapter 2.3.2, p. 21). Briefly, dipalmitoylphosphatidylcholine (DPPC), cholesterol, PEG2000-PE 
were dissolved in chloroform in a molar ratio of 61:30:9, respectively. The lipid mixture was 
desiccated under vacuum then re-dissolved in anhydrous ethanol with 1 wt % of a lipophilic 
membrane dye, 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI-C18) 
(Life Technologies, Carlsbad, CA), Carlsbad, CA)) for a total lipid concentration of 10 mM. A 
1x Phosphate Buffered Saline (PBS) (Sigma Aldrich) solution at pH 7.4 was used as the 
hydration buffer. All fluids were passed through 0.22 μm filters before being introduced to the 
microfluidic device.  
4.3.3 Microfluidic Liposome Synthesis 
 Synthesis of liposomes using the 3D-MHF annular device 
Liposomes were prepared via 3D-MHF by injecting the ethanol-lipid solution central intra-
annular line and 1x PBS into the extra-annular line composed of PVC tubing to generate an 
aqueous outer sheath flow. For typical operation, a 65 μm ID intra-annular lipid-ethanol feed line 
was used and placed at a 5 mm protrusion length from the face of the multicapillary buffer 
supply. The buffer volumetric flow rate was set to 5 mL/min and the flow rate ratio (FRR), or the 
ratio of the volumetric flow rate of buffer to the volumetric flow rate of solvent, was set to 5000. 
 Synthesis of liposomes using the 2D-MHF planar device 
Liposomes were synthesized using the microfluidic flow focusing method as described 
previously.
41–44
 Briefly, a lipid-ethanol mixture (10 mM lipid) was injected between two aqueous 
buffer inlets (1x PBS) into a PDMS glass microfluidic device with channel dimensions of 300 
µm by 50 µm. The flow rate ratio (FRR), which represents the ratio of volumetric flow rate of 




the total flow for all FRRs was kept constant (0.11 m/s) for a volumetric flow rate of 100 
µL/min.  
4.3.4 Asymmetric Flow Field-Flow Fractionation (AF
4
) with Multi-Angle Laser Light 
Scattering (MALLS) and Quasi-Elastic Light Scattering (QELS) 
Liposomes manufactured using MHF techniques were analyzed using Asymmetric Flow 
Field-Flow Fractionation (AF
4
) paired to dual Multi-Angle Laser Light Scatter (MALLS) and 
Quasi-Elastic Light Scattering (QELS) detection (Wyatt Technology, Santa Barbara, CA). The 
procedure described in Chapter 2.3.4 (p. 23) was followed for liposome characterization.  
4.3.5 Computational Fluid Dynamics (CFD) Simulation of Ethanol-Water Concentration 
Profile 
A computational fluid dynamics simulation was developed to illustrate the difference in the 
ethanol-water concentration profiles between the two distinctive microfluidic device geometries: 
annular (3D) versus planar (2D). The concentration profile of a center stream of ethanol focused 
by an exterior sheath of water was represented in a three-dimensional model created using 
COMSOL Multiphysics 4.2 software (COMSOL Inc., Burlington, MA). The non-linear 
relationship for ethanol-water of the mutual diffusion coefficient (D) to ethanol mole fraction 
(XE) was estimated using Equation 4.1, which was derived from experimental values:
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Hydrodynamic flow focusing of a radial system and a rectangular system were analyzed 
using the simulation to illustrate the difference in diminishing ethanol mole fraction within the 
two microchannel architectures. For the comparison, the FRR in the simulation was set to 100 
and total volumetric flow rate was 5.0 mL/min for the annular device and 90 µL/min for the 





simulations do not account for the nonlinearity in viscosity of the mixtures, with the assumption 
that this does not have a critical effect on the resulting concentration profile for the purposes of 
comparison. 
4.4 Results and Discussion 
The 3D-MHF system consisting of a concentric capillary array is depicted in Figure 4.1. 
Liposomes of tunable size are formed through continuous injection of an alcohol-soluble lipid 
solution into a central feed line that is radially sheathed by external aqueous buffer. As soluble 
lipids from the alcohol stream controllably diffuse into the aqueous stream, lipids self-assemble 
into liposomes. The magnitude of flow focusing and the mixing geometry at the interface 
between these two fluids play an integral role in the size and size distribution of the resultant 
liposome products.  
4.4.1 Interfacial Mixing Geometry Affects Liposome Particle Size Characteristics 
Liposome preparation via MHF has been previously demonstrated in planar microfluidic 
systems, where microchannel depth-to-width aspect ratio significantly impacts the size 
characteristics of the resultant liposomal products.
44
 It is known that hydrodynamic (or 
parabolic) flow in a rectangular channel experiences a non-uniform velocity profile across the 
vertical plane due to no-slip boundary conditions of flow streams sandwiched between the walls 
of the device. This is shown by the numerical CFD simulation in Figure 4.2A. In a controlled-
flow particle assembly system like that required for reproducible liposome formation, these so-
called "edge effects" induce asymmetric mixing at the interface between the aqueous sheathing 
fluid and the solubilized lipid at the point of particle formation, which can contribute to an 
increase in particle size polydispersity.
14
 These effects can be partially alleviated if the 






however, the practicalities of engineering rectangular microfluidic devices of increasing aspect 
ratio become increasingly more difficult and expensive.
127
  
The 3D-MHF device described here allows for an important modification in the mixing 
condition at the miscible fluid interface where particle formation occurs within the planar device 
(Figure 4.2B). Here, the lipid input is entirely encapsulated in the annular sheathing fluid, 
resulting in radially symmetric mixing and subsequent formation of liposome populations with 
previously unforeseen size uniformity (see Section 4.4.3, page 72). Comparative simulations of 
Figure 4.2: CFD simulation of ethanol concentration in (A) 2D-MHF vs. (B) 3D-MHF 
device. FRR set to 100 with linear flow velocity 0.2 cm/s (corresponding to a volumetric 
5.0 mL/min, planar Qtot=90 µL/min). Cross-sectional concentration profiles represent 




interfacial ethanol concentration from the 2D- and 3D-MHF device geometries at a distance 150 
μm downstream from the fluid mixing interface are also displayed in Figure 4.2. Clear 
differences in the depletion of alcohol at the channel wall are observed between the two 
techniques. Numerical simulation of the planar device shows that a fraction of alcohol (~0.4 
mole fraction to 0.6 mole fraction) approaches the device wall beyond the mixing interface. 
However, there is no observation of this in the 3D device, where alcohol concentration is 
completely depleted in the region approaching the device boundaries. As a result, the annular 
device enables the rapid, radially symmetric diffusion of alcohol components into the buffer, 
yielding less polydisperse populations of lipid nanoparticles.  
Representative liposome preparations made by MHF using the planar device (red trace) 
versus the annular device (blue trace) are shown in Figure 4.3. Flow conditions were chosen 
such that the average liposome radius generated by each device was similar for direct 
comparison (51 nm for 2D-MHF versus 53 nm for 3D-MHF). The annular flow device shows an 
improvement in optimal liposome size uniformity relative to the planar microfluidic device 
(Figure 4.3). This observation can be quantified from the particle size polydispersity index 
(PDI), defined as the ratio of the square of the standard deviation of particle size to the square of 
the mean diameter, a normalized measure of the size distribution.
129
 Interestingly, the average 
PDI of the resultant liposome populations decreases by half (0.083 to 0.044) when comparing the 
planar microfluidic to the annular microfluidic method.  Under some flow conditions, the annular 
flow platform was shown to produce liposomes with PDIs as low as 0.007 (not shown).  From a 
process manufacturing perspective, the 3D-MHF annular flow system maintains advantages over 
its planar flow counterpart, where it has been demonstrated to reliably produce uniform 
nanoscale vesicles up to a rate of 10
9
 liposomes/min (final lipid concentration of approximately 4 




liposomes at a lower rate 10
5
 liposomes/min (final lipid concentration of approximately 400 
µmol/L).  
4.4.2 3D-MHF Device Design Parameters Affect Liposome Size and Polydispersity 
The effect of intra-annular capillary orifice size on the resultant liposome size characteristics 
was investigated under fixed flow conditions. The dimension of the capillary orifice is related to 
the effect of microchannel size and aspect ratio in the planar MHF. It was observed that a 
reduction in intra-annular capillary ID from 255 μm to 125 μm to 65 μm correlated with resultant 
average particle radii of 72 nm, 63 nm, and 53 nm, respectively (Figure 4.4). Here, a fixed 
Figure 4.3: Comparison between 2D- and 3D-MHF liposome manufacture platforms. 
2D-MHF experiments were carried out in rectangular microchannels with a 6:1 aspect 
ratio at FRR 10 and a total volumetric flow of 200 μL/min. 3D-MHF experiments were 
carried out in a device with a 65 μm intra-annular ID lipid feed line at FRR 5000 and a 
total volumetric flow of 5 mL/min. Average liposome radius for the 2D-MHF device was 




applied volumetric flow through a smaller orifice will generate a greater linear velocity of the 
soluble lipid stream and subsequent focusing condition which, in turn, reduces the total diffusion 
distance of lipids from their solvated state in alcohol into the aqueous buffer where they 
accumulate to form vesicles due to the decreasing physical width of the lipid-ethanol flow 
stream. Although a decrease in average vesicle radii was observed with a reduction in intra-
annular capillary ID, there was no discernible effect on the resulting size distribution. The PDIs 
were comparable each of the intra-annular capillaries investigated at 0.02, 0.04, and 0.03 for the 
65 μm, 125 μm, and 255 μm ID capillaries, respectively.  
The effect of the protrusion distance of the intra-annular lipid feed capillary beyond the exit 
Figure 4.4: Effect of intra-annular orifice of lipid feed line on resultant liposome size 
characteristics using the 3D-MHF device. Volumetric flow rate and flow rate ratio of 
fluidic inputs are fixed at FRR 5000 with a total flow rate of 5 mL/min. A reduction in 
lipid feed line orifice results in a decreased-size average liposome size, likely due to the 
increased focusing condition. Average liposome radius was 53 nm (0.044 PDI) for 65 μm 




of the extra-annular sheathing fluid was also investigated at fixed flow conditions. In this 
experiment, the intra-annular capillary was positioned 0 mm from the multicapillary outlet (flush 
to the multicapillary face) and then at a length 5 mm beyond the outlet. Resultant liposome 
particle size was found to be partially linked to the extension of the intra-annular lipid feed line 
into the aqueous sheath. At a 0 mm capillary protrusion length, the average liposome size was 96 
nm with a PDI of 0.030 compared to the 5 mm protrusion length where the average liposome 
size was 53 nm with a PDI of 0.007. The difference in particle size and distribution for the two 
device constructs demonstrates that there is a critical distance from the inlet, Ze, after which the 
flow is fully developed yielding conditions for systematic particle assembly.
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 This distance can 
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Here, Q is the volumetric flow rate, A is the cross-sectional area of the annulus, ν is the 
kinematic viscosity (taken to be that of water at room temperature) , and DH is the hydraulic 
diameter of the pipe, which is defined as D(outer) - D(inner) (3.46 mm).
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 The required length that 
the intra-annular capillary must reside distal to the multicapillary outlet of the 3D-MHF device 
was calculated to be 6.7 mm at a typical operational volumetric flow rate of 5 mL/min. The 5 
mm protrusion length used in these experiments approaches this distance, which within 
placement error, enables for a platform where the sheath flow is nearly fully developed before 






4.4.3 3D-MHF Device Operational Flow Parameters Affect Liposome Size and Polydispersity 
The magnitude of the ratio of sheathing buffer to soluble lipid flow rate (FRR) and total flow 
rate of MHF systems have been previously determined to play a significant role in liposome 
synthesis. Studies using planar (2D) microfluidic platforms have shown a relationship between 
liposome size and polydispersity linked to the degree of focusing experienced by the central lipid 
feed line. 2D-MHF demonstrated that a greater magnitude of focusing, or higher FRR, leads to 
smaller, less polydisperse liposomal populations.
41–44
 
Figure 4.5: Effect of flow focusing on liposome size using 3D-MHF. Total volumetric 
flow rate was fixed at 5 mL/min. Device had a 65 μm intra-annular capillary ID. Average 
liposome radius was 53 nm (0.007 PDI) at FRR 5000, 56 nm (0.005 PDI) at FRR 1000, 




To investigate the effect of flow focusing on liposome synthesis in the 3D-MHF system, the 
flow rate ratio (FRR) of buffer to alcohol-soluble lipid was varied from 500, 1000, and 5000 and 
the resulting liposome populations were analyzed by light scattering, as described in Section 
4.3.4 (page 65). As the FRR of sheathing buffer to alcohol-solubilized lipid increased from 500 
to 1000 to 5000, the resulting average size of liposomes decreased from a radius of 66 nm to 56 
nm to 53 nm, respectively (Figure 4.5). The trend observed here correlates with that from 
previous planar device syntheses and is likewise attributed to the increasing degree of focusing 
experienced by the center stream of solubilized lipid.  
To investigate the effect of total flow rate on liposome production, 3D-MHF devices were 
operated with the volumetric flow rate of the sheathing buffer at 1 mL/min, 2 mL/min, and 5 
mL/min (Re = 4.7, 9.4, and 23.6, respectively). In these studies, a device with 65 µm ID PEEK 
tubing extending 5 mm from the multicapillary interface was used and FRR was fixed at 5000. 
The average particle size of the resulting liposomes decreased as the input flow rate increased. 
Indeed, as the total flow rate of the system increased from 1 mL/min to 2 mL/min to 5 mL/min, 
the resulting liposome average radii are reduced from 88 nm to 80 nm to 70 nm data not shown). 
Although all flow parameters investigated are laminar and significantly below the transition 
threshold into the turbulent flow regime (an inherent characteristic of most microfluidic 
systems), a modest increase in Re appears to expedite lipid accumulation and subsequent 
assembly into smaller particles. Notably, an increase in buffer flow rate does not play a role in 
particle size dispersity, likely due to a fixed alcohol concentration (fixed FRR) at the mixing 
interface which is known to play a role in the stabilization of liposomal intermediates prior to 







Microfluidic systems enable the production of nearly monodisperse populations of liposomes 
whose sizes may be adjusted by controlling the flow rates within the device during synthesis. 
This chapter presents the first demonstration of three-dimensional microfluidic hydrodynamic 
focusing for the rapid manufacture of nanoscale liposomes. 3D-MHF was achieved through the 
use of a facile and cost-effective concentric capillary array. The device enabled the continuous 
flow synthesis of nanoscale, unilamellar liposomes with unprecedentedly low polydispersity, and 
relationships between flow conditions and device parameters on the resulting liposomes were 
investigated. Liposomal populations produced by this method are of tunable size at 
unprecedented rates (10
9
 liposomes/min) without the need for any post-formation 
homogenization steps to achieve size characteristics necessary for biomedical application. 
Additionally, this technique is well suited for scale-up to support mass production of nanoscale 
liposomes which possess the beneficial qualities resulting from microfluidic synthesis with 
further improved throughput and size polydispersity over previous microfluidic techniques. The 
annular flow focusing method for liposome synthesis provides a rapid, simple avenue for the 






 : Microfluidic Preparation of Liposomes to Determine Particle Chapter 5
Size Influence on Cellular Uptake Mechanisms 
5.1 Summary 
This chapter presents a series of experiments which were completed through combined 
efforts with Dr. Abhay U. Andar at the University of Maryland Baltimore School of Pharmacy. 
The chapter is adapted from a published journal article in which Dr. Andar and I share first 
authorship. Dr. Andar performed the work regarding cell culture, endocytosis studies, flow 
cytometry, and confocal imaging. Analysis and manuscript preparation were the result of a 
combined effort from both parties. 
 Cellular uptake and trafficking of liposomes in Caco-2 cells using vesicles with distinct 
average diameters ranging from 40.6 nm to 276.6 nm is investigated in this chapter. Liposomes 
were prepared by microfluidic hydrodynamic flow focusing, producing nearly monodisperse 
populations and enabling size-dependent uptake to be effectively evaluated. Populations of PEG-
conjugated liposomes of various distinct sizes were prepared in a disposable microfluidic device 
using a simple continuous flow microfluidic technique. Liposome cellular uptake was 
investigated using flow cytometry and confocal microscopy. Liposome uptake by Caco-2 cells 
was observed to be strongly size-dependent for liposomes with mean diameters ranging from 
40.6 nm to 276.6 nm. When testing these liposomes against endocytosis inhibitors, cellular 
uptake of the largest (97.8 nm and 162.1 nm in diameter) liposomes were predominantly 
subjected to clathrin-dependent uptake mechanisms, the medium-sized (72.3 nm in diameter) 
liposomes seemed to be influenced by all investigated pathways and the smallest liposomes (40.6 
nm in diameter) primarily followed a dynamin-dependent pathway. In addition, the 40.6 nm, 




endosomes after 1 h compared to liposomes which were 97.8 nm in diameter. Conversely, 
liposome colocalization with lysosomes was consistent for liposomes ranging from 40.6 nm to 
97.8 nm in diameter. The continuous flow synthesis of nearly monodisperse populations of 
liposomes of distinct size via a microfluidic hydrodynamic flow focusing technique enabled 
unique in vitro studies in which specific effects of particle size on cellular uptake were 
elucidated. The results of this study highlight the significant influence of liposome size on 
cellular uptake mechanisms and may be further exploited for increasing specificity, improving 
efficacy, and reducing toxicity of liposomal drug delivery systems. 
5.2 Introduction 
Liposomes have received a great deal of attention as drug delivery vehicles owing to their 
ability to transport a range of therapeutic agents.
2,65,132,133
 While the utility of liposomes as 
delivery vehicles for therapeutics and vaccines has been widely recognized, many hurdles remain 
for effective delivery to targeted tissues and cells.
134
 Due to the inevitable size variability within 
a single population of liposomes prepared through conventional synthesis techniques, 
determination of an efficient size-based targeting mechanism remains a challenge. Liposome size 
and variability in size are important factors that can influence drug dosage, targeting and 
clearance,
35,37
 initial cellular recognition,
135–137
 and efficient cellular uptake and extended 
circulation time.
35,37
 The microfluidic-based technique for liposome synthesis presents a new 
avenue for producing populations of liposomes with tunable size and exceptionally low 
polydispersity compared to traditional methods.
41–44
  
This chapter investigates how endocytosis behavior in human epithelial colorectal 
adenocarcinoma (Caco-2) cells is affected by particle size by using liposome synthesized through 
the microfluidic technique, thus enabling inspection of each phenomenon with much finer 




Cellular uptake mechanisms were investigated through the use of various endocytosis inhibitors. 
Additionally, intracellular trafficking of varied liposome vesicle size was investigated over time 
using confocal microscopy, distinguishing the internalization pathways and uptake mechanisms 
used by the Caco-2 cells upon exposure to liposomes of various sizes.    
5.3 Materials and Methods 
5.3.1 Microfluidic Preparation of Liposomes 
5.3.1.1 Device Fabrication 
Microfluidic devices were fabricated using soft lithography techniques.
138
 Microchannel 
designs were created using AutoCAD software (Autodesk, San Rafael, CA) and printed onto a 
photomask (Fineline Imaging, Colorado Springs, CO). To create features for imprinting 
microchannels, SU-8 negative photoresist (MicroChem Corp., Newton, MA) was spin-coated 
onto a 4-inch silicon wafer (University Wafer, South Boston, MA), exposed to ultraviolet light 
through the photomask on an automated EVG 620 mask aligner (EV Group, Germany), and 
developed to establish a master mold with raised features which may be used repeatedly to create 
microchannels in poly(dimethylsiloxane) (PDMS) elastomer. The SU-8 mold was placed in a 
plastic petri dish and a 10:1 (w:w) mixture of pre-polymer PDMS elastomer and curing agent 
(Sylgard 184, Dow Corning Corp. Midland, MI) was poured over the mold. Vacuum was applied 
to the petri dish to remove air bubbles before being placed in a convection oven at 80 ºC for 4 h 
to ensure complete curing of the PDMS. The PDMS was carefully removed from the SU-8 mold 
and sectioned into devices by a scalpel. Inlet and outlet holes were made using a biopsy punch 
(Harris Uni-Core, Ted Pella, Inc., Redding, CA). The bonding surfaces of the PDMS and a glass 
slide were cleaned using isopropanol and DI water then exposed to oxygen plasma in a March 




mated and placed in a convection oven at 80 ºC for 2 h for bonding to occur. Microfluidic device 
channels were 15 m wide and 150 m high. 
5.3.1.2 Lipid Mixture and Hydration Buffer Preparation 
Lipid mixture preparation and hydration buffer were prepared as previously described 
(Chapter 2.3.2, p. 21). Briefly, DPPC, cholesterol, and PEG2000-PE were mixed in chloroform at 
a molar ratio of 50:40:10, respectively. The lipid mixture was desiccated under vacuum then re-
dissolved in anhydrous ethanol with 1 wt % DiI for a total lipid concentration of 15 mM. A 1x 
PBS solution at pH 7.4 was used as a hydration buffer. All fluids were passed through 0.22 μm 
filters before being introduced to the microfluidic device.  
5.3.1.3 Microfluidic Liposome Synthesis 
The PDMS-glass microfluidic devices were used to form PEGylated liposomes by including 
PEG-conjugated lipids during liposome synthesis with phosphate buffered saline (PBS) as a 
hydration buffer using the method demonstrated previous.
86
 Briefly, PBS was injected into two 
side channels intersecting with a center channel containing the ethanol/lipid mixture. The flow 
rate ratio (FRR), defined as the ratio of volumetric flow rate of aqueous buffer to that of solvent, 
was varied from FRR 3 to FRR 15 to produce liposomes of various sizes. The linear flow 
velocity of the combined fluid streams for all FRRs was kept constant at 0.20 m/s. The 
hydrodynamic focusing region within the microfluidic device was monitored with a TE-2000 S 
epifluorescence inverted microscope (Nikon, Melville, NY) during liposome formation to ensure 




5.3.1.4 Asymmetric Flow Field-Flow Fractionation (AF
4
) with Multi-Angle Laser Light 
Scattering (MALLS) and Quasi-Elastic Light Scattering (QELS) 
Liposomes manufactured using MHF techniques were analyzed using Asymmetric Flow 
Field-Flow Fractionation (AF
4
) paired to dual Multi-Angle Laser Light Scatter (MALLS) and 
Quasi-Elastic Light Scattering (QELS) detection (Wyatt Technology, Santa Barbara, CA). The 
procedure described in Chapter 2.3.4 (p. 23) was followed for liposome characterization.  
5.3.2 Cellular Uptake Studies
1
 
5.3.2.1 Caco-2 Cell Culture 
Caco-2 cells were cultured at 37 °C in an atmosphere of 95% relative humidity and 5% CO2 
(vol %). Cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS), 1% non-essential amino acids, 10,000 units/mL penicillin, 
10,000 g/mL streptomycin and 25 g/mL amphotericin B. Media was changed every second 
day and cells were passaged at approximately 90% confluence using a 0.25% 
trypsin/ethylendiamine tetraacetic acid (EDTA) solution.   
5.3.2.2 Cytotoxicity of Liposome Populations.  
Cytotoxicity tests were performed to ensure that toxicity would have no influence on cellular 
uptake. The WST-1 reagent assay was used to examine the viability of Caco-2 cells in presence 
of the differently sized liposomes at varied concentrations. Caco-2 cells, seeded at 5 x 10
5
 
cells/well, were incubated for 2 days at 37 C, 95% relative humidity and 5% CO2. Cells were 
incubated with the test liposome solution and assessed by the WST-1 assay at different 
concentrations. 90% to 95% viability was chosen as the minimum allowable concentration for 
use in uptake studies.  
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5.3.2.3 Cytotoxicity of Endocytosis Inhibitors 
Cytotoxicity of endocytosis inhibitors was assessed in Caco-2 cells to ensure the cell viability 
over short-term exposure to these chemicals during uptake experiments. Endocytosis inhibitors 
were prepared at a range of concentrations known to reduce the different pathways. Inhibitors 
used for their respective pathways were as follows: monodansyl cadaverine (Mdc) (150 M to 
600 M) for clathrin mediated endocytosis; filipin (Fil) (2 M to 8 M) for reduction of 
caveolin-mediated endocytosis; dynasore (Dyn) (25 M to 100 M) for dynamin-dependent 
endocytosis; and wortmannin (Wort) (50 nM to 200 nM) for macropinocytosis dependent 
endocytosis (The range of all the inhibitors was determined through literature
139–141
).  
Cytotoxicity of the inhibitors was assessed by the water-soluble tetrazolium salt (WST-1) assay 
(Roche Applied Science, Indianapolis, IN). Caco-2 cells were seeded at 50,000 cells per well in a 
96-well plate (Corning, NY). Cells were incubated at 37 C, 95% relative humidity and 5% CO2 
for 48 h. Cells were washed with warm Hank’s balanced salt solution (HBSS) buffer and 
incubated for 2 h with 100 L solutions containing a varied concentration of endocytosis 
inhibitors. The solutions were removed after 2 h and cells were washed twice with HBSS buffer. 
WST-1 assay reagent solution was added to each well (10 L of WST-1 in 100 L of HBSS for 
each well) and incubated for 4 h at 37 C. Following the incubation time, the plate was mixed 
well and then measured for absorbance on a plate reader. Absorbance at 460 nm and background 
at 600 nm were measured using a SpectraMax plate reader (Molecular Devices, Sunnyvale, CA). 
Cells incubated in HBSS were used as the negative control for 100% viability and cells 
incubated in Triton-X were used as the positive control. Cell viability ≥85% was classified as 
concentrations acceptable for uptake studies. The inhibitor concentrations used for the cellular 
uptake studies are represented in Table 5.2 (p. 84): Mdc at 300 M, Wort at 100 nM, Fil 4 M 




5.3.2.4 Cellular Uptake Studies 
Cellular uptake of the various sizes of liposomes was determined in the presence and absence 
of endocytosis inhibitors. Inhibitors used were at concentrations that showed a minimum of 85% 
of viability during the 2 h period of the assay incubation period. Cells were seeded at 150,000 
cell/well in a 12-well plate (Corning, NY) and grown for 3-4 days at 37 C, 95% relative 
humidity and 5% CO2. Culture medium was then removed and cells were washed twice with 
warm HBSS. The required amount of HBSS and liposome solution was added to each well such 
that the total volume was 400 L. Cells were incubated with the liposome solution for 15 min 
and 1 h at 37 C. The liposome mixture was then removed and cells were washed twice with a 1 
mL solution of ice-cold Dulbecco’s phosphate buffered saline (DPBS). Cells were then 
incubated with trypsin for 5 min, then cell culture medium was added to halt this detachment 
process. Cells were removed from plates, transferred to microcentrifuge tubes, and centrifuged 
for 4 min at 1500 rpm. After removing the supernatant, cells were washed in DPBS and finally 
fixed in 1% paraformaldehyde (in DPBS) solution. Flow cytometry was used to measure the 
cellular fluorescence using the BD LSR flow cytometer (Becton Dickenson, Franklin Lakes, NJ) 
with filters, λEx = 552 nm; λEm = 577/10 nm. A 200 L solution of 0.4% (wt %) Trypan Blue was 
added to each sample and 10,000 to 20,000 events were taken per sample for 4 repeat 
experimental samples. Percentage uptake was determined for different cell populations by the 
shift in mean fluorescence (region of interest determined using FlowJo software) in the presence 
of endocytosis inhibitors compared to the controls in HBSS. Analysis to determine the influence 
of liposome size on cellular uptake was determined by comparing the shift in mean fluorescence 
between each liposome size sample. The data for fluorescence intensity events for all liposome 
sizes recorded by flow cytometry was normalized to the total uptake of liposomes at 37 C in the 




between the uptake in presence of inhibitors by its uptake value at 4 C (uptake at 4 C 
represents the passive uptake and hence highlights the region of interest, which varied for each 
liposome size). Thus, the values presented in Figure 5.4 (p. 88) represent the percentage of 
liposomes not affected by the inhibitor.   
5.3.2.5 Intracellular Colocalization 
Intracellular trafficking of liposomes of different sizes within Caco-2 cells was investigated 
in addition to uptake mechanisms. Caco-2 cells were seeded at 5000 cell/cm
2
 on 8-chamber 
slides. Slides were used after 3-5 days of incubation at 37 C, 95% relative humidity and 5% 
CO2. Cells were washed with warm HBSS and then incubated with liposomes in HBSS for 15 
min to 1 h. After which cells were washed with ice-cold DPBS, and fixed with 4% (wt %) 
paraformaldehyde, 4% (wt %) sucrose in DPBS for 15 min. Cells were washed with 
permeabilization buffer (PBS containing 300 mM sucrose, 50 mM NaCl, 3 mM MgCl2·6H2O, 20 
mM HEPES, 0.5% Triton X 100 (vol %), pH 7.2), which was added to the samples and kept at 4 
°C for 5 minutes. The permeabilization buffer washed out twice with DPBS and later incubated 
at 37 C with blocking buffer (3% bovine serum albumin (BSA) (wt/vol) in DPBS) for 5 
minutes. Cells were washed with DPBS and primary antibodies for early endosomes (rabbit 
polyclonal early endosome antigen -1 (EEA-1; Molecular Probes) and lysosome-associated 
membrane protein 1 (rabbit polyclonal lysosome antigen – 1 (LAMP-1); Molecular Probes) (both 
solution prepared at 1:500 vol.ratio in 3% BSA solution) were added to separate cell sample 
chambers and left for 1 h in the incubator at 37 ºC. The primary antibody was then removed and 
the cells were washed 3 times with blocking buffer and then the secondary antibody Alexa Flour-
488 goat anti-rabbit IgG (Molecular probes, Carlsbad, CA) was added at 1:1000 in the blocking 
agent solution for 1 h. The cells were then washed with 0.5 vol/vol % Tween 20 in DPBS and 




phenylindole (DAPI) for 10 min to stain the nuclei. The cells were then washed twice with 
DPBS and the chambers were removed. The slides were mounted and covered with glass 
coverslips. They were allowed to dry for a few hours before they were sealed with nail varnish 
and stored at 4 C. Images were acquired using a Nikon A1 Inverted confocal laser-scanning 
microscope (Nikon Instruments, Melville, NY). Colocalization between liposomes with early 
endosomes and lysosomes was quantified using the Elements software supplied with the Nikon 
microscope. The extent of colocalization between the overlapping channels was determined 
using the Mander’s overlap coefficient (Mx(oc)), calculated directly through the Nikon Elements 
Software. The extent of colocalization between the red and green channels (Mx(oc)) was 
















In this equation, xi, coloc is the value of voxels of the overlapped red with green components, and 
xi is the value of the red component. Mx(oc) is reported for each treatment as an average of the 6 
images where the threshold was adjusted to 5% for all images in order to compensate for any 
background noise. The Nikon Elements software was used for acquisition and the Volocity 3D 
imaging software (Improvision, Lexington, MA) was used for automated determination of 
colocalization values.  
5.4 Results 
5.4.1 Microfluidic Liposome Synthesis 
Liposome solutions prepared by microfluidic flow focusing were characterized using 
MALLS and QELS in-line with AF
4
 to determine liposome diameter, size distribution, and final 





used for cellular uptake experiments ranged from 40.6 nm to 276.6 nm (Figure 5.1, Table 5.1). 
The relationship between FRR and average liposome diameter of populations made within the 
PDMS-glass device followed trends of previously demonstrated studies,
42,43
 showing an decrease 
in liposome size corresponding to an increase in FRR. The populations of liposomes created for 
this study exhibited low levels of polydispersity with very distinct diameters.  
  
Figure 5.1: Diameter range determined by MALLS and QELS in line with AF
4
. Data 
shows size and size distribution of the microfluidic-prepared liposomes. Mean diameter 
for liposomes is presented along with the size distribution (nm) for each sample. 
Liposome populations represented here are referenced by modal diameter throughout the 
text.    
Table 5.1: Liposome particles represented as mean diameter, standard deviation (SD) 
and polydispersity index (PDI) after being prepared and collected through microfluidics 




5.4.2 Size Dependent Uptake of Liposomes in Caco-2 Cells 
Caco-2 cells were incubated with liposomes, with the number of liposomes introduced from 
each sample held constant. The values for total cellular uptake were determined by flow 
cytometry with the signal normalized to liposome surface area (DiI dye was encapsulated within 
the liposomal bilayer). The resulting fluorescence data from flow cytometry indicated that 
cellular uptake was dependent on liposome size (Figure 5.2). Liposome uptake was measured 
for two different incubation time points, 15 min and 1 h, both at 37 C. The total cellular uptake 
for the smallest liposomes (40.6 nm) was significantly higher, almost a 12-fold increase, than the 
largest liposomes (162.1 nm and 276.6 nm).  Cellular uptake of the medium-sized liposomes 
Figure 5.2: Size dependent uptake of liposomes. Flow cytometry results for Caco-2 cells 
were incubated for 15 min and 1 h at 37C with liposomes ranging from 40.6 nm to 276.6 
nm in mean diameter (liposomes contained DiI-C18 lipophilic dye). Fluorescence data was 
normalized to liposome diameter, revealing the highest liposome uptake for 40.6 nm. Each 
cell population was incubated with a consistent particle concentration (2 x 10
10
 
liposomes/mL). *** indicates a significant difference (p<0.001) by One-way ANOVA test 




(86.2 nm and 97.8 nm) demonstrated an intermediate level of uptake compared to the liposomes 
on opposite ends of this size spectrum.  
5.4.3 Endocytosis Inhibitors and Their Influence on Liposome Uptake 
Four endocytosis inhibitors were used to examine the pathways of cellular uptake as a 
function of liposome size. Before initiating the uptake and transport studies, Caco-2 cell viability 
during 2 h assay time was confirmed in the presence of the endocytosis inhibitors and the 
concentrations were determined based on those found in literature.
139–141
 Inhibitor concentrations 
that showed cell viability values ≥ 80% were selected for uptake experiments (results presented 
in Figure 5.3 and Table 5.2). Monodansyl cadeverin (MDC), a clathrin-mediated endocytosis 
pathway inhibitor, was used at a concentration of 300 M for cell studies. At this concentration, 
Figure 5.3: Cytotoxicity of endocytosis inhibitors. Cell populations were incubated for 2 
h at 37C with various endocytosis inhibitors. The graph indicates the percentage of cell 
viability for the different concentrations for each endocytosis inhibitor and results are 




little toxicity was observed compared to the maximum tested concentration of 600 M. Filipin 
(FIL), which inhibits the caveolae-mediated endocytosis pathway by binding to cholesterol 
inside caveolar pits and disrupting the pathway cycle, was used at a concentration of 4 M for 
cell uptake experiments. Wortmannin (WORT), which inhibits the process of macropinocytosis, 
did not show a considerable level of toxicity at any of the tested concentrations (50 nM to 200 
nM), thus 100 nM concentration was used for inhibition experiments as shown previously in 
literature.
141
 Dynasore (DYN), an inhibitor which is responsible for vesicle scission during both 
clathrin- and caveolin- mediated pathways and selectively inhibits dynamin 1 and dynamin 2 
GTPases during uptake,
140,142
 showed increasing toxicity over the concentrations tested with an 
acceptable viability value at 50 M, the value chosen for subsequent experiments.  
It has been reported that liposomes are predominantly endocytosed through either the 
clathrin- or caveolin- mediated endocytosis.
143–145
 Since liposomes prepared via microfluidics 
exhibit significantly decreased variability in size and polydispersity compared to those made 
through traditional processes, the present experiments are able to distinguish the uptake 
pathways experienced by each population of distinctly-sized liposomes and elucidate specific 
relationships between endocytic fate and vesicle size. The effect of vesicle size on cellular 
uptake was compared at different conditions of temperature (37 C and 4 C) and in the presence 
of each respective endocytosis pathway inhibitor at 37 C. 





Uptake of liposomes at 4 C represents passive cellular uptake: at this low temperature there 
is a global suppression of all active endocytotic pathways, thus any liposome uptake at 4 C is 
completely dependent on the ability of the particle to be passively internalized through the cell 
membrane. Conversely, the uptake of liposomes at 37 C in the absence of endocytosis inhibitors 
represents total cellular uptake when all available endocytosis mechanisms within Caco-2 cells 
may be fully utilized. In Figure 5.4 and Table 5.3, the effects on uptake in presence of 
endocytosis inhibitors are represented (all normalized to the total uptake at 37 C, which 
Figure 5.4: Liposome uptake in presence of endocytosis inhibitors. Liposomes of 
different sizes (162.1 nm, 97.8 nm , 72.3 nm  and 40.6 nm) were used for uptake studies 
in presence of endocytosis inhibitors. Data is normalized to the total uptake at 37 C 
(100%) and passive uptake at 4 C (starting point, 0%). The graph represents the 
percentage of liposomes that are not affected by inhibitors, monodansyl cadeverin 
(MDC)(300 M), wortmannin (WORT)(100 nM), filipin (FIL)(4 M), and dynamin 
(DYN)(50 M). All presented as the mean with error bars representing the standard 
deviation with n = 4  (10,000 to 20,000 events each sample repeat ‘n’). Figure generated 




represents 100% total uptake in absence of endocytosis inhibitors, and passive uptake at 4 C). 
Therefore, any difference between the uptake at 37 C and the uptake under the influence of 
inhibitors represents the liposome uptake hampered by the inhibitor, while the difference 
between the uptake of liposomes in the presence of endocytosis inhibitors and the uptake at 4 C 
represents the amount of liposomes not influenced by the pathway. Relative values of uptake are 
expressed in Figure 5.4, and absolute values of liposomal uptake presented in Table 5.3.  
The presence of MDC (clathrin-mediated pathway inhibitor) caused a much greater 
inhibition of cellular uptake of 72.3 nm diameter liposomes compared to the other sizes, 162.1 
nm, 97.8 nm, and 40.6 nm (Figure 5.4). An almost complete suppression of uptake was mainly 
observed for the medium sized liposomes (72.3 nm), suggesting that the 72.3 nm liposomes may 
rely on the clathrin-dependent uptake mechanism for entry into Caco-2 cells. In contrast, MDC 
caused minimal effect on the uptake of the smallest liposomes (40.6 nm). These observations 
suggest that 40.6 nm diameter liposomes might be exploiting a clathrin-independent pathway for 
entry into Caco-2 cells.  
In the presence of WORT, (macropinocytosis uptake pathway inhibitor), the smaller 
liposomes (40.6 nm) experienced little change in their uptake as compared to the other sizes, 
suggesting that this pathway may not significantly influence their entry into Caco-2 cells. WORT 
Table 5.3: Total liposome uptake in presence of endocytosis inhibitors, represented by 
absolute values of number of liposomes endocytosed (x10
9
), normalized to the total uptake at 




pathway inhibitor like the MDC inhibitor, caused almost complete inhibition in cellular uptake of 
72.3 nm liposomes (Figure 5.4), suggesting that this size range may also be majorly influenced 
by the macropinocytosis uptake mechanism. The larger 162.1 nm and 97.8 nm liposomes were 
not very greatly influenced by this pathway in comparison to the other sizes.  
Upon exposure to FIL (Figure 5.4), (caveolar-mediated endocytosis inhibitor), there was 
very little inhibition in cellular uptake of the larger liposomes (97.8 nm and 162.1 nm), but an 
increased inhibition of small- and medium-sized liposomes (40.6 nm and 72.3 nm). These results 
suggest the possibility of small- and medium-sized liposomes following caveolae-mediated 
(clathrin-independent) endocytosis pathways, as opposed to their larger counterparts. 
Under the presence of DYN (dynamin inhibitor), nearly complete inhibition of cellular 
uptake of small- and medium-sized liposomes (40.6 nm and 72.3 nm) was observed, whereas 
larger 97.8 nm and 162.1 nm diameter liposomes were not affected much by the inhibitor in 
comparison. 
In conclusion, exposure to the combination of inhibitors of specific endocytosis pathways 
and liposomes of various sizes has been studied here to elucidate size-based uptake mechanisms 
experienced by Caco-2 cells in culture. When deriving a comparison between the effect of 
inhibitor on cellular uptake of liposomes of different sizes, the size ranges of 162.1 nm and 97.8 
nm appeared to not be heavily influenced for most of the tested pathway inhibitors. However, 
this comparison is more interesting when made between the different inhibitors within each size 
of liposome. For example, MDC and DYN have a slightly greater effect on the uptake than FIL 
and WORT for 162.1 nm liposomes, possibly suggesting that this size could possibly be 
influenced by a clathrin- and dynamin- dependent endocytosis pathways. Additionally, MDC 
seems to have the most effect compared to the other pathway inhibitors (FIL, DYN and WORT) 




size range. All pathway inhibitors tested here influenced the uptake of 72.3 nm diameter 
liposomes, indicating that liposomes of this size may have the ability to be taken up through 
several mechanisms within Caco-2 cells. Finally, the smallest tested liposomes (40.6 nm) were 
mainly inhibited by DYN, indicating that the fate of particle internalization may depend 
primarily on a dynamin-dependent endocytosis pathway. Dynamin-dependent pathways include 
caveolar- and clathrin-mediated pathways, but also include some alternative pathways. 
Therefore, a combination of the effect of the effect of DYN, FIL, and WORT provide interesting 
information of the Caco-2 cells and their liposomal uptake mechanisms.  
5.4.4 Intracellular Trafficking Using Confocal Microscopy 
Intracellular trafficking of liposomes was observed in addition to determining their uptake 
mechanisms (Figure 5.5). Liposomes were expected to colocalize with the endosomes and 
Figure 5.5: Colocalization of liposomes with EEA-1 and LAMP-1.Intracellular trafficking of 
liposomes was measured after 1 h incubation with Caco-2 cells. Colocalization between 
liposomes and endosomes (EEA1)/lysosomes (LAMP1) was measured using Mander’s 
overlap coefficient (Mx(oc)). Results are reported as the mean with error bars representing 
standard deviation (n=8), where * represents a significant difference for (p < 0.05) by One-




lysosomes over time, thus the goal for this experiment was to see the differences in 
colocalization between the varied liposome sizes and endosome (EEA-1) or lysosome (LAMP-1) 
compartments after 1 h of incubation at 37 C. From Figure 5.5 and Figure 5.6, a trend was 
observed in the colocalization of liposomes, where the much smaller 40.6 nm and 72.3 nm 
liposomes colocalized with the endosomes slightly less than the 97.8 nm and 162.1 nm diameter 
liposomes. Although more than 40% of the 40.6 nm liposomes appear to have colocalized with 
endosomes, it may be possible that the remaining 60% may move further down the trafficking 





Figure 5.6: Confocal imaging of colocalization of liposomes with endosomal regions. 
Caco-2 cells incubated for 1 h with DiI-C18 (red) fluorescently labeled liposomes: A) 40.6 
nm, B) 72.3 nm, C) 97.8 nm, and D) 162.1 nm liposomes. Endosomes were stained using 
AlexaFluor 488 (green) for anti EEA1 antibody. These samples were examined by 
confocal microscope (Nikon A1).  The nucleus was stained with Dapi. The arrows in the 





Figure 5.7: Confocal imaging of colocalization of liposomes with lysosomal regions. 
Caco-2 cells incubated for 1 h with DiI-C18 (red) fluorescently labeled liposomes: A) 40.6 
nm, B) 72.3 nm, C) 97.8 nm, and D) 162.1 nm liposomes. Lysosomes were stained using 
AlexaFluor 488 (green) for anti Lamp-1 antibody. These samples were examined by 
confocal microscope (Nikon A1).  The nucleus was stained with Dapi. Arrow in the 




Figure 5.5 and Figure 5.7 show that 72.3 nm and 40.6 nm liposomes are more highly 
colocalized with the LAMP-1 lysosomal region than with EEA-1 endosomal regions. The 72.3 
nm diameter liposomes colocalizing with the LAMP-1 regions much more compared to any of 
the other tested sizes, suggesting that a higher percentage of these diameter range liposomes 
might accumulate in the lysosomes and drug release may be quicker and more effective.    
5.5 Discussion 
Microfluidic technology enabled the production of nearly monodisperse populations of 
liposomes with distinct diameters for size-specific cellular uptake studies. For this study, 
liposomes were prepared using an established microfluidic method where solutions of nearly 
monodisperse liposomes were achieved through hydrodynamic flow focusing.
41
 Here, this 
method was adopted to prepare populations of liposomes for novel cellular uptake studies in 
which the relationships between endocytosis mechanisms and vesicle sizes were analyzed with 
high specificity. The ability to control liposome size and polydispersity, to an extent, has 
potential to have a large impact on numerous drug delivery applications and could improve upon 
currently available liposome-based drugs by rendering them more site-specific and efficient.
136
 
In order to design effective liposomal drug delivery systems, it is critical to also understand the 
detailed mechanisms of their cellular trafficking and transport.
135
 In this chapter, liposomes 
prepared within microfluidic devices, via hydrodynamic flow focusing,
41,42
 ranged in mean 
diameters of 40.6 nm to 276.6 nm. 
The overall cellular uptake of liposomes over time (15 min and 60 min at 37 C) was 
observed to be dependent on liposome size in Caco-2 cells. Total cellular accumulation was 
higher for the smallest liposomes (40.6 nm) and for the medium range liposomes (72.3 nm) in 
comparison to the largest liposomes (276.6 nm) (Figure 5.2). This illustrates the significant 




over time. When considering liposome based drug targeting for in vivo conditions the circulation, 
accumulation, in vivo drug release and clearance have been extensively studied revealing that 
amongst other things, size is an important factor when considering a vehicle for drug 
delivery.
37,109
 Previous studies have shown a positive correlation to the effect of liposome size on 
the rate of clearance from blood and also suggesting that a decrease in the liposome size may 
reduce recognition by components in blood, like the mononuclear phagocytic system (MPS).
37
 
Although in some cases liposome delivery and effectiveness is also dependent on the lipid 
composition 
139,146,147
 and surface charge or chemistry,
22,148,149
 it has been shown that size is also 
a major factor determining effectiveness of drug delivery.  When considering liposome delivery 
for antitumor drugs, size appears to be a major factor affecting drug permeation into the in vivo 
tumor environment and local tumor tissue, where the optimal size has been shown to in the range 
of ≤100 nm.
37,109
 This size range has also been shown to accumulate more within tumor tissues 
compared to much larger sizes.
37
 However, a liposome size of 100 nm may not always be 
optimal for all tumors, since tumor conditions such as the pore size of a given tumor’s vessels 
varies depending on the type of tumor, site of the growth, size of the tumor and the regression of 
the tumor site.
150,151
 This study reveals the higher in vitro effectiveness of smaller (40.6 nm) 
liposomes compared to much larger (97.8 nm to 276.6 nm) liposomes on uptake in Caco-2 cells, 
therefore suggesting that the former may be a more relevant size for specific targeting 
applications when translating this study to in vivo conditions. 
Size-dependent liposome internalization was also evaluated by focusing on four major 
cellular uptake pathways: clathrin-mediated, caveolin-mediated, macropinocytosis and dynamin-
dependent pathways, using liposomes with distinct diameters ranging from 40.6 nm to 162.1 nm. 
These endocytosis pathways represent unique internalization mechanisms by which cells respond 




of coated pits by the assembly of the protein clathrin, which forms a triskelion-like shape 
composed of three clathrin heavy chains and three light chains.
137
 Upon endocytosis of particles, 
the coated pits form vesicles which are typically 120~150 nm in diameter.
136,137,152
 The caveolae-
mediated pathway is dependent on the protein caveolin, which binds cholesterol to sphingolipids 
in certain areas and forms flask-like invaginations of the cell plasma membrane. Caveolae 
vesicles range approximately 50~80 nm in diameter.
136,137
 The macropinocytosis pathway is a 
clathrin- and caveolin- independent, actin-dependent process where the protrusions from the cell 
membrane collapse onto and fuse with the plasma membrane to generate large endocytic vesicles 
ranging from 500~1000 nm in diameter (depending on the cell type).
136,137
 Macropinocytosis 
pathways are not size specific and can internalize small to large particles. The dynamin-
dependent pathway is an important receptor-mediated pathway in which the enzyme dynamin 
pinches vesicles from the plasma membrane during endocytosis.
153,154
 Some studies suggest that 
dynamin may also be involved in certain caveolae- and clathrin-independent pathways, including 
the Ras homolog gene family member A (RhoA)-dependent pathway, cell division control 
protein 42 (Cdc42)-dependent pathway, and flotillin-dependent pathways.
153
 Studies have also 
suggested that dynamin may self-assemble into rings (typically 30~50 nm in diameter) which 
constrict invaginated coated pits around their necks to form budding coated vesicles.
155
 
In these experiments, the dynamin-dependent pathway appeared to specifically influence the 
smaller 40.6 nm liposomes. Interestingly, 72.3 nm diameter liposomes were also seemingly 
affected by the dynamin-dependent pathway, while the 97.8 nm to 162.1 nm liposomes were 
nearly unaffected. The larger 97.8 nm to 162.1 nm liposomes were not influenced by any of the 
four pathways tested as much as the smaller 72.3 nm and 40.6 nm liposomes. The larger 162.3 
nm liposomes seemed to be more affected by the MDC and DYN inhibitors than the FIL and 




clathrin- and dynamin- dependent pathways. The 97.8 nm liposomes were more highly 
influenced by MDC in comparison to the other inhibitors (i.e. FIL, WORT and DYN), 
suggesting that this size range may be the most highly influenced by the clathrin-dependent 
endocytosis pathway.  In contrast, the 72.3 nm liposomes appear to be affected by all tested 
pathway inhibitors, suggesting this may be a useful size range for drug delivery applications 
since it utilizes most of the major trafficking pathways within cells. 
Chemical inhibitors have a varied effectiveness in different cell lines and have the ability to 
be somewhat non-specific,
140
 therefore liposome particles may behave differently depending on 
cell type and these results may only be true specifically for cellular uptake in Caco-2 cells. 
Intracellular trafficking experiments, including confocal microscopy, shed further light 
intracellular fate of the liposomes after cellular uptake. Colocalization between the liposomes of 
varied size with endosomal and lysosomal markers was reported in Caco-2 cells. Early 
endosomal accumulation of 97.8 nm diameter liposomes was much greater than lysosomal 
accumulation after 1 h of incubation. The 72.3 nm liposomes appeared to be more highly 
accumulated within lysosomal regions compared to endosomal regions after 1 h incubation. A 
similar trend was observed for the 40.6 nm diameter liposomes, where a slightly higher 
lysosomal accumulation was observed in comparison to the endosomal regions. These 
observations suggest that greater amounts of the 40.6 nm and 72.3 nm diameter liposomes travel 
to lysosomes for degradation compared to their larger counterparts, which is a key step in the 
effective targeting and drug release.
137
 Conclusively, these findings demonstrate a size 
dependence of liposomes on both overall cellular uptake in addition the various specific 
mechanisms which come into play during the endocytosis process. 
Previous studies probing the cellular uptake and trafficking of liposomes have been based on 






 thus the ability to highlight the true fate of each individual vesicle size 
within the range of interest was limited. This study utilizes the ability of microfluidic mixing of 
chemical species to produce nearly monodisperse populations of liposomes with distinct, varying 
size for cellular uptake studies. The benefits of the microfluidic technique for liposome synthesis 
are highly advantageous for increasing specificity and efficacy while reducing toxicity of 
liposomes for drug delivery applications. Additionally, microfluidic liposome preparation is a 
continuous flow, one-step process; limits reagent consumption; and may be a more cost effective 
method for liposome production due to expenses for liposome production in both academia and 
industry.
156
 The ability to synthesize homogenous populations of liposomes also permits a higher 
level of control over the intracellular fate of the drug carrier, thus aiding in more sophisticated 
design of liposomal drug delivery systems. Through these unique studies, the advantages of the 
microfluidic method for liposome synthesis have been highlighted by producing liposomes of 
very distinct sizes and showing highly specific interactions with Caco-2 cells in vitro which 
reveal a size dependence on both overall uptake as well as intracellular fate.  
5.6 Conclusion 
This chapter reports a detailed study of cellular uptake mechanisms and intracellular 
trafficking related to the uptake of liposome populations prepared by an established microfluidic 
flow focusing technique. The unique ability of microfluidic flow focusing to produce nearly 
monodisperse populations of liposomes with distinct sizes is highly advantageous for increasing 
the specificity for drug delivery applications. These findings reveal that intracellular uptake of 
liposomes in Caco-2 cells is size dependent and that overall uptake increases with a decrease in 
particle size. Specific endocytosis mechanisms involved in the uptake of liposomes also depend 




dynamin dominant uptake pathway. Additionally, the slightly larger liposomes (97.8 nm to 162.1 
nm in diameter) did not show any significant dependency on any particular uptake pathways that 
were tested in comparison to their smaller counterparts, while in comparison to other larger 
liposomes a slight dependency on the clathrin-mediated pathway was observed. A unique 
observation from this study was the dependence of an intermediate size of liposomes (72.3 nm) 
on almost every endocytosis mechanism tested. In addition, the 72.3 nm liposomes showed the 
highest accumulation within lysosomal regions inside the Caco-2 cells in comparison to the other 
sizes of liposomes. In conclusion, microfluidic liposome preparation has enabled the 
demonstration of the important role of liposome size on facilitating the particle recognition by 
particular cellular mechanisms. In future work, the microfluidic technique for liposome synthesis 
may be utilized to further assist in designing more effective populations of liposomes for various 





 : Size-Dependent Dermal Transport of Microfluidic-Enabled Chapter 6
Liposomes 
6.1 Summary 
This chapter presents a series of experiments which were completed through combined 
efforts with Dr. Eric L. Kendall at the University of Maryland College Park. The chapter is 
adapted from a submitted journal article in which Dr. Kendall and I share first authorship. 
Experimental work, analysis, and manuscript preparation are a result of equal effort from both 
parties. 
Microfluidic synthesis of small and nearly monodisperse liposomes is used to investigate the 
size-dependent passive transdermal transport of nanoscale lipid vesicles. While large liposomes 
with diameters above 105 nm are found to be excluded from deeper skin layers past the stratum 
corneum, the primary barrier to nanoparticle transport, liposomes with mean diameters between 
31 nm to 41 nm exhibit significantly enhanced penetration. Furthermore, multicolor fluorescence 
imaging reveals that the smaller liposomes pass rapidly through the stratum corneum without 
vesicle rupture. These findings reveal that nanoscale liposomes with well-controlled size and 
minimal size variance are excellent vehicles for transdermal delivery of functional nanoparticle 
drugs. 
6.2 Introduction 
Transdermal drug delivery offers significant potential as an alternative to oral delivery and 
hypodermic injection due to the promise of pain-free local or systemic introduction of drugs with 
controllable delivery rates over extended time periods.
157
 Effective delivery of drug through the 




20 µm thick tissue region comprised of a structured lipid/protein matrix.
158,159
 Even when 
employing chemical penetration enhancers, a broad class of skin disrupting molecules including 
a variety of surfactants,
157,160
 transdermal drug delivery has met only limited success. Techniques 
such as dermabrasion and thermal ablation can temporarily render the SC porous to enhance drug 
transport, but these methods require active disruption of the skin and do not allow controlled 
doses to be delivered over long time periods. Similarly, non-invasive active methods such as 
ionophoresis and ultrasound require specialized equipment and only enhance drug transport for 
short periods. Nanoparticles are an alternative strategy for passive transdermal delivery, offering 
increased drug loading, sustained release, and the potential for tissue-specific targeting. The 
structure of the SC includes lamellar lipid regions that present sub-nanometer intercellular spaces 
which can be widened in the presence of nanoparticle colloids to pores with dimensions on the 
order of several tens of nanometers.
159,161
 Inorganic quantum dots ranging from approximately 4 
nm to 12 nm in diameter exhibit efficient passive transport across the SC.
162,163
 However, the 
utility of these nanoparticles for drug delivery is limited by high toxicity and low drug loading 
capacity.
164
 In contrast, lipid nanoparticles present a highly attractive route for drug delivery due 
to their excellent biocompatibility.
65
 In particular, nanoscale liposomes with lipid bilayers 
encapsulating aqueous internal volumes offer high loading of both hydrophilic and amphipathic 
drugs, low toxicity, and tunable stability. However, there is little evidence that lipid vesicles 
ranging from 60 nm to several micrometers in diameter can traverse the SC in significant 
numbers,
165–168
 nor is there clear evidence of intact liposome passage through the SC. As a result, 
the application of lipid nanoparticles for transdermal drug delivery has largely focused on 




 which incorporate surfactants or 
alcohols to impart a high degree of flexibility to the vesicle membranes, putatively allowing 




systemic delivery through the bloodstream, these nanoparticles are not ideal since large and 
flexible liposomes are subject to rapid opsonization and phagocytotic clearance. Furthermore, 
whereas both pharmacokinetics and biodistribution of traditional liposomes have been 
extensively studied and optimized, the behaviors of flexible liposomes remain largely unknown. 
More fundamentally, recent evidence indicates that ultraflexible transfersomes are highly 
compromised by passage through the skin, and may be no better than traditional liposomes for 
transdermal delivery of intact vesicles.
170
 
This chapter leverages a microfluidic technique that employs hydrodynamic focusing of a 
stream of solvated lipid sheathed by a sheath flow of aqueous buffer within a continuous flow 
process.
41,42,44,86
 This approach provides the ability to generate well-defined populations of small 
liposomes with narrow size distributions, enabling the effective study of the size-dependent 





 are limited in their ability to generate well 
defined populations of liposomes with diameters in the size range expected to support effective 
transport of nanoparticles through the SC. As a result, prior studies have not shown extensive 
penetration of traditional liposomes past the SC.
165–168
 In the present study, the capacity of the 
microfluidic technique to produce small liposomes with low polydispersity was exploited to 
generate populations of dye-laden vesicles that are almost entirely within the 25 nm to 40 nm 
diameter range previously reported to result in high transdermal flux of other monodisperse 
nanoparticles.
171,172
 Microfluidic-enabled liposome preparations with mean diameters ranging 
from 31 nm to 308 nm were prepared. Within this size range, two classes of liposomes were 
formed that differed by the incorporation of small amounts of either anionic lipids or PEGylated 
lipids, enabling the influence of surface chemistry on trans-SC flux to be investigated. For all 




liposomes ranged from 0.035 to 0.135; as a comparison, a previous study investigating vesicles 
as small as 120 nm reported the use of liposomes with polydispersity indices varying from 0.1 to 
0.3.
173
 Overall, the microfluidic-enabled liposomes produced here are both smaller and more 
narrowly distributed in diameter than bulk scale produced liposomes used in prior passive 
transdermal drug delivery studies. The use of smaller liposomes is significant due to the 
hypothesis that liposomes, like other nanoparticles 
159,161,171,172
 will exhibit size-dependent 
dermal transport, with vesicles smaller than approximately 40 nm in diameter traversing the SC 
more effectively than larger nanoparticles. Similarly, the low polydispersity is significant since 
the total fluorescence signal from a vesicle population with a wide size distribution will be 
biased by the presence of significant number of liposomes above the mean diameter, prohibiting 
accurate evaluation of transport as a function of vesicle size. While a French press technique for 
liposome preparation has been reported to enable the formation of small unilamellar vesicles 
with diameters below approximately 30 nm to 50 nm,
174,175
 this method does not allow vesicle 
size to be readily tuned. The exceptionally low polydispersity of the microfluidic-enabled 
liposomes over a wide range of diameters allows a unique view into size-dependent dermal 
transport. 
6.3 Materials and Methods 
Ethics Statement. This research involved Yorkshire piglets sacrificed as part of a separate 
parallel study approved by the Institutional Animal Care and Use Committee (IACUC) at the 
Children’s National Medical Center. All procedures were performed in accordance with the 




6.3.1 Lipid Mixture and Hydration Buffer Preparation 
Two variations of lipid mixtures were prepared to analyze the resulting penetration depth of 
both PEG-conjugated (PEGylated) and negatively-charged (anionic) into dermal tissue. In 
addition to enhancing liposome stability, PEG is commonly attached to the exterior of liposomes 
as a protective shield from the immune system during blood circulation,
3
 potentially increasing 
the bioavailability of PEGylated liposomes that are able to reach and enter subcutaneous 
capillaries after transdermal transport. Lipid mixture preparation and hydration buffer were 
prepared as previously described (Chapter 2.3.2, p. 21). Briefly, for PEGylated liposomes, 
DMPC, cholesterol, and PEG2000-PE were combined in chloroform at a molar ratio of 70:25:5 
(respectively). For anionic liposomes, DMPC, cholesterol, and anionic surfactant DCP were 
mixed in chloroform at a molar ratio of 50:40:10 (respectively). All lipid mixtures were 
desiccated under vacuum then re-dissolved in anhydrous ethanol (Sigma Aldrich) for a total lipid 
concentration of 40 mM. To assist in fluorescent imaging, DiI was included into the lipid 
mixtures (1 wt%). A 1x PBS (10 mM) solution at pH 7.4 was used as a hydration buffer, with 
selected samples containing 1 mM hydrophilic sodium fluorescein salt (SF) (Sigma Aldrich) as a 
hydrophilic dye. All fluids were passed through 0.22 μm filters before being introduced to the 
microfluidic device. 
6.3.2 Liposome Synthesis and Characterization 
PEGylated and anionic liposomes were prepared using methods described previously.
41,42,44,86
 
Briefly, a flow focusing microchannel network for liposome synthesis was fabricated following 
previous work.
176
 All microchannels in the final device were nominally 50 µm wide and 300 µm 
tall. The prepared lipid-ethanol solution was injected into the microfluidic device between two 
sheath flows of the aqueous buffer. The FRR was varied from 5 to 50 to produce liposomes with 




for all FRRs was kept constant (0.125 m/s) for a total volumetric flow rate of 112 µL/min. To 
enable the formation of smaller vesicles, the temperature of the microfluidic device was 
controlled by contacting the glass slide of the device with a hot plate at 50 °C throughout the 
entire synthesis process.
93
 The resulting liposome populations were characterized for size via 
dynamic light scattering (Nano ZSP, Malvern Instruments Ltd., UK). Size distribution plots were 
generated by fitting spline curves to the binned distribution data imported from the dynamic light 
scattering instrument.  
The microfluidic-generated liposomes contained lipophilic DiI in their bilayers and 
hydrophilic SF in their cores to enable fluorescence imaging of tissue penetration depth. To 
remove any remaining dye not incorporated into the liposomes during the synthesis process, all 
liposome samples were purified via size exclusion chromatography on Sephadex G-25 PD-10 
columns (GE Healthcare, Piscataway, NJ) equilibrated with PBS immediately before application 
to the tissue. Gel filtration using the PD-10 columns provides efficient buffer exchange for 
removal of ethanol used in the liposome formation process, thereby preventing variations in 
Figure 6.1: Volume-weighted size distributions of microfluidic-enabled (A) PEGylated 
and (B) anionic liposomes, revealing narrow size distributions over the full size range 




ethanol concentration (2–16%) used for different liposome populations from affecting skin 
permeation experiments. Final lipid concentrations following gel filtration ranged from 0.56 mM 
to 4.76 mM, depending on the FRR used for liposome synthesis. 
6.3.3 Tissue Exposure and Cryosectioning
2
 
Porcine ear tissue from Yorkshire piglets (4 weeks, 5 kg) was selected due to its 
morphological and functional resemblance to human skin. Porcine ear skin in vitro has shown 
remarkably similar biophysical properties to human skin in vivo, particularly in terms of the 
diffusivity and permeability coefficient of water across the SC.
177
 Studies have also indicated 
that porcine skin is extremely similar both structurally and chemically to its human counterpart, 
exhibits chemical properties which are rather consistent across different samples and stable over 
time at room temperature, therefore porcine skin is a valuable tool for investigating diffusion 
dynamics of materials with human skin.
178
 One ear from each animal was removed following 
general anesthesia. Liposome solutions were immediately applied in 50 µL aliquots for each size 
in different locations on the outside of the ear, resulting in spot areas ranging from 0.25–0.5 cm
2
, 
and incubated for 15 min at room temperature. This exposure method was chosen over the use of 
a perfusion cell since the focus of this study is on short-term SC transport rather than long-term 
behavior of the nanoparticles within the dermis. For the characterization of size-dependent 
transport, all liposome solutions covering the full range of size distributions were deposited on 
ears from a single animal to minimize the influence of tissue morphology variations between 
animals. Different animals were used for each set of experiments characterizing PEGylated 
liposome transport, anionic liposome transport, and co-distribution of lipophilic and hydrophilic 
dyes.  Following incubation, the ear tissue was placed in a plastic petri dish and frozen. The 
                                                 
2
 The experiments in Section 6.3.3 and Section 6.3.4 were performed through the combined efforts of Renee Hood and Dr. Eric 




frozen tissue was bulk sectioned, embedded using Tissue-Tek Cryo-OCT compound (Fisher 
Scientific, Pittsburgh, PA), and frozen at 80 °C. The frozen tissues blocks were then sectioned 
into smaller slices, nominally 30 µm thick and revealing dermal tissues at least 300 µm from the 
surface, using a HM550 cryostat microtome (Richard Allan Scientific, Kalamazoo, MI) and 
placed onto gelatin-treated glass slides for imaging. Sections were procured from the tissue 
directly beneath each of the applied liposome volumes, with the plane of each section aligned 
through the center of its corresponding droplet. Sectioning was performed with the blade 
oriented perpendicular to the skin surface and the blade path in the direction of the SC to prevent 
artifacts that could result from mechanical displacement of liposomes, dye, or tissue normal to 
the SC layer. 
6.3.4 Fluorescence Microscopy and Image Processing 
The 30 µm thick tissue sections were imaged using a TE-2000 S inverted epifluorescence 
microscope (Nikon, Melville, NY). Brightfield images and fluorescence images at 528 nm – 553 
nm (green filter; DiI) and 465 nm – 495 nm (blue filter; SF) excitation wavelengths were 
acquired and overlaid to confirm and evaluate the extent of liposome penetration into the dermal 
tissue and to assess colocalization of the lipophilic and hydrophilic dyes.  
ImageJ software (National Institutes of Health, Bethesda, MD) was used to analyze the 
images. Fluorescence intensity profiles were extracted using 10 µm wide regions of interest 
(ROIs), with data from multiple ROIs combined to generate quantitative profiles of liposome 
penetration depth. The intensity data was averaged across 5 ROIs per sample, then normalized to 
peak intensity and aligned to reveal the average fluorescence signal seen within each tissue 
sample below the SC. Dye colocalization was analyzed using the JACoP plugin with ImageJ.
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6.4 Results and Discussion  
6.4.1 Transdermal Liposome Penetration 
Fluorescence microscopy of microtomed porcine ear tissue after incubation with the various 
liposome preparations shows a marked difference in the dermal penetration of dyes between 
tissues exposed to either larger or smaller liposome preparations. Figure 6.2 shows 
representative fluorescent images revealing the distribution of DiI dye within the tissue sections. 
Skin samples exposed to the larger 105 nm to 308 nm liposomes (PEGylated and anionic) 
consistently exhibit bright bands of fluorescence associated with the SC, with very little 
fluorescence within deeper skin layers, revealing that these larger liposomes are either physically 
Figure 6.2: Brightfield/fluorescence image overlays (top) and single-channel 
fluorescence images (bottom) for microtomed tissue sections following 15 min 
application of PEGylated or anionic liposome samples of varying diameters containing 
DiI lipophilic dye. Significant dye penetration past the SC is observed with the smallest 
liposomes (31 nm diameter PEGylated and 41 nm anionic liposomes), while dye from 
the larger vesicles does not appear to cross the SC, indicating size-based passive 




excluded by the narrow inter-corneocyte spaces, or are ruptured in the process of traversing the 
SC. In the latter case, the lipids and lipophilic dyes from the ruptured liposomes are likely to 
adhere to or associate with surrounding cells and extra-cellular material.
180
 Conversely, the 
smaller 31 nm and 41 nm liposomes reveal a more evenly distributed dye profile throughout the 
skin, appearing to traverse the SC and enter the underlying layers of tissue in multiple instances 
with less significant accumulation in the SC (Figure 6.2). Several bright features that appear in 
deeper layers within some images are believed to be a result of imperfections caused by vessels 
or voids created during cryosectioning. Skin locations with capillaries were excluded due to the 
known autofluorescence of whole blood between wavelengths of 450-600 nm
181
 and the 
relatively low concentration of fluorescent molecules in the liposome samples. Regions with 
significant voids created by tearing of the thin tissue sections during microtoming were excluded 
in order to maintain consistency throughout the samples. In control samples using free SF dye 
applied to the skin in liposome-free buffer, no penetration beyond the SC was observed. Dye 
penetration into deeper skin layers shows a strong dependence on liposome size, irrespective of 
charge state as determined by the presentation of PEG or anionic lipids on the vesicle surfaces.  
This is consistent with the hypothesis that dermal transport of lipid vesicles is a size-based 
phenomenon, and the ability of the smallest liposomes to traverse the SC and reach lower layers 
of skin is a direct result of the reduced liposome diameters. In some samples, bright and highly 
localized defects were visible in the dermis and epidermis. These features are routinely observed 
in dermal transport studies, and are the result of enhanced particle transport through hair-
follicles, pores, and skin perforations.
182,183
 This uneven, defect-based liposome penetration 
pathway is, by nature, not highly correlated to liposome size.
182,183
 The more diffuse, evenly 
distributed fluorescence signal seen in the epidermis in the small (31 nm and 41 nm) liposome 




similar phenomenon seen with other nanoparticles below 40 nm in diameter.
159,161,171,172
 For 
tissue samples where hair follicles were present, enhanced transport was observed for all 
liposomes populations. Results from these samples were omitted from analysis to prevent the 
confounding influence of follicular transport on analysis of SC penetration and to highlight the 
effect of transdermal diffusion of the liposomes through pathways which do not rely on follicular 
transport.  
For quantitative comparison of liposome penetration, ImageJ software was used to obtain 
plot profiles of fluorescence intensity normal to the tissue surface. Profiles of each tissue section 
were averaged over 5 representative regions per sample (Figure 6.3). These profiles were 
normalized for maximum fluorescence intensity per profile and aligned to the midpoint of the 
SC, across all samples. The SC thickness was determined from averaged manual measurements 
using brightfield images of each tissue, ranging from 15 µm to 40 µm, which is in agreement 
with previously reported values for porcine skin.
184
 The percentage of DiI fluorescence intensity 
observed beneath the SC compared to the total observed fluorescence signal was calculated from 
Figure 6.3: DiI fluorescence intensity plot profiles for (a) PEGylated liposomes and (b) 
anionic liposomes as a function of porcine skin tissue penetration depth. Measurements 
were performed 15 minute following liposome application. Each curve is representative 




the plot profiles for each sample and compared across different liposome sizes and surface 
chemistries (Figure 6.4). This technique assumes a linear relationship between fluorescence 
intensity and liposome concentration, an assumption that does not hold for samples where 
liposomes are highly concentrated in one area causing a local saturation of fluorescence 
intensity, as observed in some images from the larger (diameter greater than 105 nm) liposomes 
used in this study. This saturation effect leads to systematic underreporting of liposomes trapped 
Figure 6.4: Percentage of total DiI fluorescence signal seen below the SC for the 
different sizes of PEGylated and anionic liposomes. Each plot reflects the average profile 
extracted from 5 ROIs per tissue section, with error bars reflecting standard deviation. SC 
thickness, estimated from averaged manual measurements using brightfield images of 
each tissue, ranged from 15 µm to 40 µm, in general agreement with previously reported 
values for porcine skin.
184
 The small 31 nm PEGylated liposomes pass the SC in large 
numbers (91%), which is up to 590% greater than the larger 105 nm to 308 nm diameter 
liposomes. The small 41 nm anionic liposomes also reveal 65% of their total DiI signal 
under the SC, which is 200% greater than observed with 256 nm diameter liposomes of 




in the SC, and thus a bias toward higher measured penetration efficiencies for these larger 
liposomes can occur. Detector saturation was avoided as much as possible while maintaining 
identical imaging conditions across all samples used in this study. While efforts were made to 
omit from analysis tissue sections with large voids, blood vessels, or hair follicles, some regions 
with anomalous fluorescent patches do appear in several images, particularly for the larger 308 
nm PEGylated liposomes as seen in Figure 6.2.  
The small 31 nm PEGylated liposomes pass the SC in large numbers (91%), which is up to 
590% greater than the larger 105 nm to 308 nm vesicles studied here. The small 41 nm diameter 
anionic liposomes show 65% of their total DiI signal under the SC, which is 200% greater than 
observed with 256 nm diameter liposomes. Both populations of smaller liposomes exhibit 
significantly enhanced penetration through dermal tissues compared to the larger vesicles, which 
is consistent with the behavior observed for other nanoparticles smaller than 40 nm in 
diameter,
171,172
 and reveals that size-dependent transdermal transport of the microfluidic-enabled 
liposomes follows the same overall trend observed for other classes of nanoparticles.  
6.4.2 Colocalization of Liposomal Dyes 
Regardless of their transport efficiency, it has been unclear if liposomes can traverse the SC 
intact. Penetration of fluorescent reporter molecules may occur as a result of liposome rupture or 
leakage during passage through the SC, with enhanced permeation of free dye possibly resulting 
from interactions between liposomes and dermal lipid structures. To explore this issue for the 
case of the microfluidic-enabled liposomes, a combination of hydrophilic dye (SF) and lipophilic 
dye (DiI) were simultaneously incorporated during liposome formation into the vesicle cores and 
bilayers, respectively. Due to the lipid structure of the SC, diffusive transport of free hydrophilic 
and hydrophobic solutes is expected to vary significantly,
185,186
 such that a lack of spatial 




allowing the hydrophilic dye (SF) to permeate through the tissue at a different rate than the 
lipophilic dye (DiI).  Conversely, a high degree of spatial correlation would suggest the presence 
of intact vesicles. For the case of 31 nm liposomes, two color imaging of the exposed tissue 
sections reveals strong agreement between the distributions of hydrophilic (green) and lipophilic 
(red) signals through the SC and into the epidermis for all samples, as revealed through both the 
images (Figure 6.5) and the dye penetration depth profiles taken along the depth of the tissue 
(Figure 6.6). Using Pearson’s correlation coefficient (ρ) as a measure of the degree of linear 
dependence between the spatial distributions of each dye, an average value of ρ =0.92 was 
determined for the 31 nm PEGylated liposomes, indicating a high degree of correlation between 
Figure 6.5: Brightfield images of 3 representative tissue regions following application of 
31 nm PEGyated liposomes to porcine skin tissue (top), together with matched single 
channel fluorescence images for lipophilic DiI (middle) and hydrophilic SF (bottom). 
Similar fluorescence distributions for both dyes are seen across multiple tissue sections, 




the dye locations. While not conclusive, this evidence strongly suggests that the small liposomes 
successfully penetrate through the SC intact with minimal leakage of their cargo. Experiments 
performed using larger liposomes resulted in measured values of ρ =0.81 and ρ =0.75 for 308 nm 
and 105 nm liposomes (Figure 6.6), respectively. This relatively poor correlation, together with 
the overall lack of significant dye penetration (Figure 6.3), indicates that some degree of vesicle 
degradation and free dye diffusion occurs for these larger liposomes.   
6.5 Conclusion 
This chapter leverages a microfluidic liposome synthesis technique to evaluate size-
dependent transdermal delivery of liposomes through ex vivo porcine tissues. Compared to larger 
Figure 6.6: Penetration depth profiles of lipophilic and hydrophilic liposomal dyes 
within a tissue section following 15 min application of 31 nm PEGyated liposomes 
simultaneously loaded with both dyes. Each curve is representative of an average of 5 
ROIs per image. A Pearson’s correlation coefficient of ρ = 0.92 reveals a high degree of 




vesicles, where dye penetration across the SC is presumed to occur primarily through a 
combination of vesicle rupture and transport along follicular pathways, the smaller 31 nm 
diameter and 41 nm diameter liposomes traverse and transport their intra-liposomal contents 
across the full surface of the SC and into deep dermal tissues, with penetration depths of at least 
several hundred micrometers observed with a short 15 min incubation. Multicolor fluorescence 
imaging of hydrophilic and hydrophobic dyes incorporated into the liposomes during synthesis 
further reveals that the smallest 31 nm liposomes are able to traverse dermal layers intact, with 
implications for clinical applications requiring co-delivery of therapeutic reagents with dissimilar 
chemical properties, nanoparticle-mediated drug release, or transport of intact nanocarriers to the 
bloodstream for systemic delivery. The results presented here also represent the first 
demonstration of passive transdermal diffusion of nanoscale, microfluidic-generated liposomes, 
opening the door to the use of these nanoparticles for effective delivery of lipophilic, 
hydrophilic, and amphipathic compounds to underlying dermal layers. The transport of 
nanoparticles through the SC is a matter of much debate, and the findings of the present study 
will require additional validation using complementary methods to confirm the size-dependent 





 :  Conclusion Chapter 7
7.1 Dissertation Summary 
 In this dissertation, an established technique for microfluidic-directed liposome synthesis is 
advanced through the incorporation of additional on-line preparation methods and the 
demonstration of its usefulness through practical applications. Through the incorporation of 
large, functionalized lipids during liposome synthesis, the capability of the microfluidic 
technique to produce stealth, tumor-targeted liposomes which are relevant for a variety of drug 
delivery applications is demonstrated. By integrating additional functionalities to the 
microfluidic device including rapid buffer exchange via microdialysis and remote loading of 
amphipathic compounds in-line with liposome synthesis, the ability to further prepare samples of 
liposomes for use in drug delivery applications through an integrated, continuous flow 
microfluidic process has been proven. Investigating microfluidic-directed synthesis of liposomes 
through 3D flow focusing within a concentric capillary device requiring simple, inexpensive 
fabrication techniques enabled the examination of the impact of edge effects created during flow 
focusing in the typical 2D microfluidic device and the confirmation of the ability of the 
technique to produce liposomes in an apparatus with a different geometry, in addition to 
addressing the topic of scale up by producing liposomes at a rate which is a factor of 10
4
 
liposomes/min faster than the existing method. To demonstrate the usefulness of microfluidic-
enabled liposomes for practical applications, the value of microfluidic-enabled liposomes in drug 
carrier design was revealed by preparing liposomes with distinct diameters to investigate size-
based interactions with high resolution within a cancer cell line (Caco-2) in vitro. Additionally, 
transdermal delivery of liposomal carriers was investigated by utilizing the microfluidic method 




penetration of liposomes through ex vivo porcine skin. The collection of research presented here 
advances the established microfluidic method for liposome synthesis from a pilot technique to a 
more useful, practical system which is highly amendable for widespread use for a multiplicity of 
drug delivery applications. 
7.2 Proposed Future Efforts 
The research presented in this dissertation sets a solid foundation for a variety of subsequent 
efforts to further progress the microfluidic liposome synthesis platform. It should be noted that 
the technique described here has difficulty with reproducing similar size distributions with 
identical experimental conditions. Although this is a disadvantage, it is not extremely 
problematic as general the overall trends regarding the relationship between flow conditions, 
temperature, lipid compositions, etc. remain constant despite the variation in conditions for a 
given experiment. This is a feature which should be further explored to improve repeatability. 
For many applications, only a single size of liposome is necessary, thus the experimental 
parameters can be tweaked until the desired size is produced. Aside from this issue of 
repeatability, the following forthcoming research endeavors are proposed: 
7.2.1 Microfluidic Synthesis of Immunoliposomes 
As this dissertation improved the existing liposome synthesis technique through the 
incorporation of on-chip microfluidic buffer exchange and remote drug loading, additional 
functionalities may be incorporated for even further enhancement. One potentially valuable 
preparation technique for the device is in-line tethering of antibodies to liposome exteriors after 
synthesis. Studies in this dissertation focused on the use of folate to produce tumor-targeted 
liposomes; although folate is an effective targeting ligand for many diseases, there remain many 




fragments for effective targeting.
187
 Unlike folate, which has a low molecular weight (~440 Da) 
compared to the native lipid (600~800 Da) and the attached PEG (2000~5000 Da), both 
monocloncal antibodies and antibody fragments are quite large in molecular weight (150 kDa 
and 28~50 kDa, respectively). Consequently, lipids with pre-conjugated antibodies are too large 
to use for synthesizing liposomes through the microfluidic technique, with increasing difficulty 
as the resulting particle radius decreases. Thus, antibody-functionalized liposomes, or 
“immunoliposomes”, must be formed through the attachment of antibodies to pre-formed 
vesicles.  
Immunoliposomes are most commonly produced through the attachment of antibodies or 
antibody fragments to preformed liposomes using either coupling chemistry or post-insertion of 
antibody-functionalized lipids.
188
 Through coupling chemistry, liposomes are formed with 
PEGylated lipid whose terminal ends contain a functional group (e.g., biotin) and after formation 
are incubated with an antibody or antibody fragment which contains the appropriate functional 
group (in this case, streptavidin) to form a covalent or non-covalent bond with the vesicle 
membrane’s outer leaflet, resulting an in immunoliposome.
189
 The ability to form PEG-modified 
liposomes has been verified by the work presented in this dissertation, hence liposomes could be 
generated via microfluidic flow focusing using functionalized PEG lipid then introduced to 
functionalized antibodies or antibody fragments downstream of synthesis. 
Alternatively, post-insertion involves the incubation of preformed liposomes with micelles of 
PEG-lipid derivatives (e.g., PEG-PE), during which time the micelles spontaneously transfer 
their lipid molecules to the liposomes’ membranes’ outer leaflets to reduce the free energy of the 
hydrophobic lipid tail due to the higher radius of curvature within micelles.
190
 Eventually, the 
micelles completely incorporate themselves into the lipid vesicles to form functionalized 




to days), the decreased diffusion lengths within microfluidics could potentially facilitate a more 
rapid lipid transfer from the micelles into the liposomes in addition to a more uniform 
distribution of antibodies on the exterior monolayer.  
Through either of these methods, liposomes could be generated using the established flow 
focusing method followed by downstream antibody conjugation for the in situ generation of 
immunoliposomes. These microfluidic immunoliposome formation strategies could be optimized 
to create customized lipid formulations which result in different antibody densities and types by 
simply changing the flow conditions within the device. 
7.2.2 Passive Encapsulation Methods 
This dissertation focused on the active encapsulation of drugs using a transmembrane ion 
gradient, a method which is extremely valuable the wide range of drugs which are amphipathic 
weak bases. However, the list of molecules which benefit from liposomal delivery is actively 
expanding and many of these molecules (e.g., bioactive molecules, uncharged molecules, etc.) 
cannot traverse liposomal bilayers and therefore must still be encapsulated using traditional 
passive methods. Microfluidics also has an advantage for these techniques over bulk scale 
loading due to the decreased volumes used for production. Previous efforts have focused on 
passive liposome encapsulation during microfluidic liposome synthesis (see Figure 1.6, p. 13), 
in which the liposomes are formed directly adjacent to a thin stream of highly concentrated 
reagent, thereby encapsulating the highest possible concentration of solute during vesicle 
formation while eliminating waste.
43
 In addition to optimizing this method (i.e. encapsulant 
concentration, flow rate ratios, etc.), downstream functionalities for collecting the leftover 
reagent which was not encapsulated could be incorporated and this extra reagent could be 




Another technique which is commonly used to enhance passive encapsulation of reagents 
into liposomes is freeze-thaw cycling,
191
 in which dispersions of liposomes undergo multiple 
cycles of being frozen within a liquid nitrogen (-196 °C) bath and being thawed in a warm water 
(~50 °C) in order to bring the lipids above and below their melting point. This process assists in 
matching the interior liposome volume’s solute concentration to that of the hydration buffer 
(equilibrium solute concentrations also cause an imbalance between interior and exterior 
environments
192
). Typically performed through a bulk scale process, this method could also be 
accomplished within a microfluidic system in which a device could be fabricated on a thin, heat 
resistant substrate such as microscope cover glass (<100 µm) and a segment of the channel 
downstream from liposome formation and reagent introduction could serpentine through two 
various chip segments: with on-chip heaters and one with an off-chip cooling block which 
delivers liquid nitrogen (Figure 7.1). This microfluidic passive encapsulation method could be 
Figure 7.1: Schematic of a 3-inlet for microfluidic passive encapsulation via freeze-thaw 
cycling in-line with liposome synthesis. The device contains a serpentine channel 
downstream of the flow focusing region through a “freeze” region containing a liquid 





optimized for the encapsulation of materials such as DNA, siRNA, peptides, and other molecules 
which are not amendable to the active loading process. 
7.2.3 High Throughput Microfluidic Liposome Preparation 
Perhaps one of the most critical areas to address through forthcoming efforts to further 
develop the “pharmacy-on-a-chip” technique is scale up. Although this dissertation demonstrates 
a device which can produce liposomes on the order of milliliters per minute, a more rapid 
approach utilizing the 2D system would be ideal, particularly as this device geometry is more 
Figure 7.2: Simulation of the vertical focusing chip and diminishing mole fraction of 
ethanol along the length of the device. Height of microchannels is defined by cover glass 
or thin spin-coated PDMS, while the width of the channel exceeds 1 mm, enabling high 




amendable to the further development of downstream functionalities. There are two basic 
strategies for achieving higher throughput of the 2D technique: scale up and size up.  
To scale up, the microfluidic flow focusing technique can be implemented within a chip 
which has a very large width (millimeter scale) and narrow height (micron scale) and the flow 
focusing occurs perpendicular to the direction of tradition Y-channel flow focusing (Figure 7.2). 
This could be achieved through the fabrication of multilayer microfluidic devices made from 
materials such as thin cover glass, spin coated films of PDMS, adhesives, other thin film 
materials, or a combination of the above. Such a device would allow for much higher throughput 
as a result of the higher potential flow rates due to increased width dimension which results in a 
lower pressure system while delivering the same quality of liposomes due to the characteristic 
dimension of the device (height) remaining on the microscale. For example, a device with 
dimensions defined by 50 µm cover glass which are 3 mm wide, as depicted in Figure 7.2, 
would provide liposomes at a rate 10x faster than the devices used in the studies presented in this 
Figure 7.3: High-volume production of single and compound emulsions in a microfluidic 
parallelization arrangement coupled with coaxial annular device. This system could be 
adapted to the flow focusing method for microfluidic liposome preparation for high-






dissertation (typically 50 µm wide by 300 µm tall) while operating under identical linear flow 
velocities. These vertical focusing devices could be optimized to provide a higher throughput 
system for generating extremely uniform populations of liposomes.  
To size up, a network of microchannels containing multiple flow focusing elements 
contained within a single device could be fabricated (Figure 7.3). As previously demonstrated 
for high volume production of droplets,
193
 the system would contain flow focusing elements in a 
parallelized arrangement coupled with a coaxial annular device fluidic circuit. Such a device 
would only require one inlet per fluid species and one outlet, resulting in one-step, high volume 
production of liposomes prepared via microfluidic hydrodynamic flow focusing.  
7.2.4 Preclinical Research 
Microfluidic liposome synthesis is poised to have a significant impact on numerous 
biomedical applications. The preliminary efforts demonstrated in the chapters of this dissertation 
have provided interesting and potentially very important information regarding the effect of a 
liposome’s size on its fate for both cellular uptake mechanisms and passive delivery through the 
skin. To specifically advance the research presented here, further studies highlighting the effect 
of particle size on liposome interaction within an in vitro environment as well as in vivo studies 
to explore liposome fate versus size within the bloodstream could be performed. Using the 
microfluidic technique, populations of liposomes with a wide range of distinct diameters and 
surface chemistries could be readily prepared and used to elucidate the interactions with specific 
tissues and the bloodstream when administered systemically. Such studies could result in the 
ability to design drug carriers with an unprecedented level of sophistication which are 
specifically optimized for a wide variety of diseases. 
To further investigate passive transdermal delivery of microfluidic-enabled liposomes, 






 to learn the effect of size on penetration depth over longer time periods. 
Additionally, in vivo studies could be utilized for the topical application of sub-40 nm liposomes 
which encapsulate various reagents. Topical liposome application would be followed by the 
measurement of neural activity or periodic collection and analysis of blood samples in order to 
investigate the effect of actual encapsulated therapeutics to passively traverse dermal layers and 
reach a viable target site. The ensuing information from these studies could be useful for 
developing transdermal drug delivery systems with prolonged release profiles, or to optimize 
delivery to different locations under the skin. 
7.3 Closing Remarks 
This dissertation presents a series of original research in which an established method for 
microfluidic-directed production of nearly monodisperse liposomes with tunable sizes was 
revolutionized through the incorporation of functionalized lipids during synthesis for production 
of tumor-targeted liposomes, the addition of new on-chip functionalities to enable microfluidic 
preparation of nanoscale drug carriers, and the implementation within a variety of substrate 
materials and microchannel geometries to render the technique more amendable for widespread 
use. Liposomes within size ranges enabled by the microfluidic synthesis technique were then 
exploited for innovative pharmaceutical and preclinical studies, highlighting genuine advantages 
of the technique through practical applications. Finally, various forthcoming research endeavors 
regarding the continuous evolution of the microfluidic technique have been suggested. With 
further evolution and optimization, microfluidic-directed synthesis and preparation of liposomal 
drug carriers has the potential to support instantaneous generation of populations of purified, 
tissue-targeted liposomal drug formulations containing high concentrations of drugs with 
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